Smart Biotech Scientist | The CMC and Biomanufacturing Podcast for Bioprocess Development and Manufacturing Leaders

What if the best way to unlock durable, broad-spectrum immunity is to rethink the very vessels delivering our vaccines?While much of the industry focuses on refining existing delivery systems, Christopher Locher is charting a new course—one inspired by nature’s own couriers. Imagine a future where oral vaccines and modular, on-demand manufacturing aren’t just possibilities, but standard practice.Christopher Locher, CEO and Co-founder of Versatope Therapeutics, brings decades of experience in drug discovery from Vertex Pharmaceuticals, Opsona Therapeutics, and Maxigen. In this episode, he shares his journey from high school science classrooms to the helm of a company pioneering recombinant extracellular transport vesicles—nanovesicles that promise to transform vaccine delivery and immunomodulation.Topics discussed:How basic scientific curiosity and the inspiration from teachers sparked Christopher's career in biotechnology (03:39)The unmet needs in vaccine development for infectious and parasitic diseases, especially in regions below the equator (04:17)Engineering nanovesicles as immunomodulators and drug delivery vehicles, using microbial bioreactors for production (06:38)Co-producing proteins and vesicles in a single process, and the flexibility of the platform (08:28)Key benefits of Versatope's platform, such as cost efficiency, stability, and commercial scalability compared to mammalian exosomes (09:53)Prospects for multi-specific vaccines and the future direction for scalable bioprocessing (11:47)Adapting manufacturing processes and overcoming logistical challenges—from COVID-related shutdowns to supply chain bottlenecks (12:21)Strategies for navigating evolving regulatory requirements with agencies like the FDA, and experience with fast IND allowance (14:53)Analytical and characterization challenges of complex nanovesicle-based products versus simpler platforms like antibodies (17:30)The vision for decentralized or local vaccine manufacturing, especially in resource-limited settings (19:12)Smart insight: Christopher Locher highlighted that the FDA allowed their IND submission for a universal influenza vaccine in less than a month after review—and notably, with no hold clinical questions—when it was submitted just before the Christmas holidays and allowed on January 19th, 2025. This rapid regulatory turn-around was made possible by a strong regulatory team and collaborative CDMO efforts, showcasing how innovative platforms and well-prepared submissions can accelerate early-stage clinical development in biotech.If Christopher's vesicle platform has you thinking about building a novel modality on an unconventional host, these four episodes go deeper on alternative production systems, microbial scale-up, and the CMC and cost decisions that get a first-in-class biologic to patients.Episodes 217 - 218: Silkworm Biomanufacturing: From Ancient Silk Production to Phase I Vaccine Trials with Masafumi OsawaEpisodes 239 - 240: Continuous Microbial Manufacturing: From Genetic Instability to 40-Day E. coli Processes with Juergen MairhoferEpisodes 231 - 232: From IND to BLA: The Biologics CMC Decisions That Determine Regulatory Success with Henri KornmannEpisodes 267 - 268: Why Affordable Insulin Is a Money Problem, Not a Science Problem with Eric MoyalConnect with Christopher Locher:Website: www.versatope.com LinkedIn: www.linkedin.com/in/christopher-locher-biotechSupport the show

How do you take a model that works in process development and get it accepted for use in GMP manufacturing? That question stalls most bioprocess modeling projects before they start. Ignasi Bofarull-Manzano, Senior Data Scientist and CMC Consultant at Körber Pharma, pushes back on the premise: the process you run today is already governed by a mathematical model, fitted once at small scale during process characterization and then left untouched for years, even as the process shifts.Part 1 separated digital models from digital shadows and digital twins, and made the case for starting with the decision rather than the data. Part 2 goes into the plant: what regulators actually require, what the numbers looked like on a real biologics process, and where a team should start on Monday morning.Topics covered:Core differences—and surprising similarities—between modeling in development versus manufacturing (02:35)Regulatory requirements: credibility assessments, model risk, and validation steps for digital twins (05:07)Real-world example: How deploying an end-to-end process model led to 35% yield increase for Takeda, and considerations for ROI in manufacturing (08:34)Advice for startup leaders on when to invest in modeling and how to scale efforts case-by-case (11:42)Steps for scientists new to modeling: identifying bottlenecks, starting simple, and proving value offline before scaling up (12:26)The importance of understanding basic statistics before relying on AI-generated models (15:22)A stepwise summary for deploying digital modeling effectively in biotech (16:01)Smart insight: The digital twin is the last step, not the first. Identify the bottleneck, build the simplest model that supports the decision, and concatenate it end to end so you can see how a parameter moves final drug substance quality rather than one unit operation's output. Prove the value offline. Only then connect interfaces, because that is where the cost and the validation burden live. Teams that lead with the twin arrive at the C-level with a proof of concept and no evidence. Teams that lead with the offline model arrive with a number.Before a digital twin can earn its keep, you need connected data, the right model, and a clear decision for it to support. These four episodes cover that ground — data silos, hybrid and mechanistic modeling, and twins built to survive regulatory scrutiny.Episodes 215 - 216: From Data Silos to Autonomous Biomanufacturing: Digital Twins and AI-Driven Scale-Up with Ilya BurkovEpisodes 05 - 06: Hybrid Modeling: The Key to Smarter Bioprocessing with Michael SokolovEpisodes 17 - 18: How Extracting Gold From Your Data Accelerates Process Development with Ioscani Jiménez del ValEpisodes 263 - 264: Why AI and Automation Tools Won't Deliver Until Your Lab's Data Is Connected with David HardyConnect with Ignasi Bofarull-Manzano:LinkedIn: www.linkedin.com/in/ignasi-bofarullKörber Pharma website: www.koerber-pharma.comSupport the show

Most bioprocess teams believe a digital twin demands vast datasets and sophisticated models. Ignasi Bofarull-Manzano argues both assumptions are wrong, and that the data already sitting in your Excel files, historians and ELNs is probably enough to start.Ignasi Bofarull-Manzano, Senior Data Scientist and CMC Consultant at Körber Pharma, breaks down what a digital twin actually is, where modeling pays back fastest across the product lifecycle, and how to tell a real business case from an expensive proof of concept.In this episode:Misconceptions about data requirements for digital twins—why quality and context of data matter more than sheer quantity (02:40)Ignasi’s journey from curiosity in biology to a career in data science, modeling, and digital twins (04:31)Clear distinctions between digital models, digital shadows, and digital twins, explained with real-world analogies (06:42)How to approach digital development when faced with legacy data silos and scattered analytics (09:56)The importance of starting with a focused business need instead of chasing trends or buzzwords (12:28)Insights into where modeling truly delivers value in the product lifecycle—development versus manufacturing (13:11)Strategies for small companies to leverage digitalization and data from the ground up (15:56)An accessible overview of physics-informed AI, physical AI, and hybrid modeling—and their application in bioprocessing (18:15)The comparative advantages of physics-informed AI versus hybrid models in different bioprocessing contexts (24:45)Smart insight: Do not start with the model. Start with the bottleneck. Identify the business need first, then the decision the model must support, then the minimum data required for that context of use. Build the model offline, concatenate it end to end across unit operations rather than optimizing one in isolation, and prove the value before connecting a single interface. Teams that skip this sequence end up building models because models sound impressive, and those projects get expensive before they get useful.Before a digital twin can earn its keep, you need connected data, the right model, and a clear decision for it to support. These four episodes cover that ground — data silos, hybrid and mechanistic modeling, and twins built to survive regulatory scrutiny.Episodes 215 - 216: From Data Silos to Autonomous Biomanufacturing: Digital Twins and AI-Driven Scale-Up with Ilya BurkovEpisodes 05 - 06: Hybrid Modeling: The Key to Smarter Bioprocessing with Michael SokolovEpisodes 17 - 18: How Extracting Gold From Your Data Accelerates Process Development with Ioscani Jiménez del ValEpisodes 263 - 264: Why AI and Automation Tools Won't Deliver Until Your Lab's Data Is Connected with David HardyConnect with Ignasi Bofarull-Manzano:LinkedIn: www.linkedin.com/in/ignasi-bofarullKörber Pharma website: www.koerber-pharma.comSupport the show

How do you turn a lab-born regenerative medical device into a solution that surgeons actually want to use and investors want to back? The path from academic innovation to clinical adoption is full of practical hurdles and strategic pivots, where compelling science alone isn’t enough.David Brühlmann welcomes back Eva-Maria Balet, whose journey spans tissue engineering research at EPFL to leading Regenosca through first-in-human trials, fundraising, and an executive MBA completed while running the company. This conversation covers the practical realities behind that journey, from quality control to clinical setbacks to investor pitches.Topics discussed:Defining TissueSpan’s regulatory path and quality control as a medical device (02:49)The significance of first-in-human studies and what early clinical experience reveals (04:11)Selecting an initial clinical indication and opportunities for technology expansion (05:50)Realistic assessment of where soft tissue repair technologies apply—and where they do not (07:18)The stepwise progression from in vitro to animal models in product development (08:18)Navigating setbacks, including the impact of Covid-19 on clinical trials, and the value of adaptability (10:36)Bridging science and business in biotech fundraising and communication (12:15)Key takeaways from pursuing an executive MBA alongside building a biotech company (13:42)The importance of collaboration, mindset, and meaningful networks in driving biotech innovation (15:19)Smart insight: The transition from scientist to founder brought its own learning curve. Eva-Maria pursued an executive MBA while running Regenosca, and points to financial and business vocabulary as the skill she'd have built earlier if she could. For a technical founder or CMC lead, the lesson isn't to become a business generalist, it's that the moment you're translating a manufacturing process or clinical dataset into an investor pitch, fluency in the language of accounting, market strategy, and cost structure becomes as load-bearing as the science itself.This week's episode with Eva-Maria Balet steps out of bioprocessing into MedTech, following a collagen scaffold from EPFL lab bench to first-in-human implant. These back-catalog picks cover similar ground: what it takes to win investor buy-in beyond the science, the discipline of turning a lab process into GMP manufacturing, why regulatory classification shapes a product's whole trajectory, and what it really takes to commercialize a lab discovery.Episodes 259 - 260: Why Strong Science Isn't Enough to Get Funded: What Investors Actually Look For with Michael RomeEpisodes 257 - 258: Why Regulatory Affairs Belongs in Drug Design: 30 Years of CMC Lessons from Discovery to GMP Manufacturing with Milan TomicEpisodes 105 - 106: From Proteins to Cell Therapy: Why ATMPs Aren't Just Complex Biologics with Oliver KraemerEpisodes 183 - 184: From Lab to Market: Secrets to Commercializing Cutting-Edge Biotech Innovations with Chervee HoConnect with Eva-Maria Balet:LinkedIn: www.linkedin.com/in/eva-maria-balet-72561737 Regenosca website: www.regenosca.comSupport the show

Imagine a wound too large for the body to close on its own. That's the problem Eva-Maria Balet set out to solve, not with living cells, but with a structural bridge that lets the body's own healing mechanisms do the rest.In this episode, David Brühlmann welcomes Eva-Maria Balet, Co-Founder & CEO of Regenosca. Trained at EPFL, Eva-Maria brought her fascination with cellular "factories" from academia straight into entrepreneurship. Rather than chasing elegant science for its own sake, she built her company around a single principle: start with a real clinical need and build backward, collaborating with clinicians from day one so every experiment serves a patient.Highlights & Topics:Why starting with clinical needs—not just scientific excitement—creates meaningful real-world impact in life sciences (02:38)How Eva-Maria’s fascination with biotechnology guided her from cell factories to developing scaffolds for tissue repair (03:51)The unmet challenges in current soft tissue repair treatments and where new solutions are needed (05:51)What makes Regenosca’s fully-engineered collagen implant, TissueSpan, different from existing meshes and biological materials (07:09)The biological mechanisms behind tissue regeneration using a temporary collagen scaffold (08:28)Translating lab-scale research into a robust, scalable, and regulatory-compliant production process (10:34)The practical realities and hurdles of navigating the medical device vs. biologic regulatory pathways (11:59)Advice on building regulatory expertise into your founding team or leveraging consultants effectively (13:31)The importance of interdisciplinary teams and trust when forming biotech startups (14:36)Smart insight: Eva-Maria put it plainly: what works in the lab has to work reliably every single time you produce it for a patient. That shift, from proving a concept to controlling a process, from raw materials through in-process controls to final product testing, is the same discipline any CMC scientist recognizes: science alone doesn't get a product to patients. Reproducibility does.This week's episode with Eva-Maria Balet steps out of bioprocessing into MedTech, following a collagen scaffold from EPFL lab bench to first-in-human implant. These back-catalog picks cover similar ground: what it takes to win investor buy-in beyond the science, the discipline of turning a lab process into GMP manufacturing, why regulatory classification shapes a product's whole trajectory, and what it really takes to commercialize a lab discovery.Episodes 259 - 260: Why Strong Science Isn't Enough to Get Funded: What Investors Actually Look For with Michael RomeEpisodes 257 - 258: Why Regulatory Affairs Belongs in Drug Design: 30 Years of CMC Lessons from Discovery to GMP Manufacturing with Milan TomicEpisodes 105 - 106: From Proteins to Cell Therapy: Why ATMPs Aren't Just Complex Biologics with Oliver KraemerEpisodes 183 - 184: From Lab to Market: Secrets to Commercializing Cutting-Edge Biotech Innovations with Chervee HoConnect with Eva-Maria Balet:LinkedIn: www.linkedin.com/in/eva-maria-balet-72561737 Regenosca website: www.regenosca.comSupport the show

Building a cell therapy company is hard. Building a genetically engineered iPSC therapy for the brain, on a preclinical budget, is one of the hardest translational problems in biotech. Every experiment has to move the program closer to an IND, or it's motion without progress.That's the operating constraint Bilal Fares faces as CEO and co-founder of AzureCell, the University of Geneva spin-off engineering neuroprotective iPSC neurons for Parkinson's disease. In Part 2, he walks through how his team decides what to build, where AI and synthetic biology genuinely accelerate a CMC roadmap, and the four founder lessons he wishes he'd internalized earlier, including his conviction that scientists who use AI will replace those who don't.Topics discussed include:Strategies for prioritizing experiments and narrowing focus with limited resources (03:33)How business opportunity validation programs helped define a product roadmap (04:08)Integrating AI and synthetic biology into research programs—and where these tools do, and don’t, accelerate development (05:07)Building a cell therapy platform for personalized approaches in neurological diseases beyond Parkinson’s (06:38)Lessons learned in biotech leadership and why tackling big problems matters (08:08)Key advice for aspiring biotech entrepreneurs: kill your own solutions quickly, and learn from others (09:27)The importance of having a strong team and how a powerful mission attracts top talent (12:21)AzureCell’s near-term plans and future goals, including upcoming fundraising and R&D milestones (13:30)Smart insight: What separates successful biotech ventures from the rest? According to Bilal Fares, it is not just technical skill but mindset. First, choose a problem large enough to be worth the struggle. Second, try to “kill your solution as fast as possible”—engage experts, enter competitions, and seek brutal feedback early so you can pivot, improve, or abandon as needed. And finally, plan with the end (approval, patients, impact) always in sight.If you enjoyed this, check out these episodes on cell therapy, where engineered cells can survive and do more than replace what's lost: Michael Rome's investor lens rounds it out for founders facing the same funding realities.Episodes 269 - 270: How to Turn Mesenchymal Stem Cells into Programmable Cancer Delivery Vehicles with Jun Yung WooEpisodes 253 - 254: How to Source, Manufacture, and Scale the Earliest Stem Cells for Allogeneic Cell Therapy Without Ethical Barriers with Yuta LeeEpisodes 249 - 250: How T Cell Activation Redefines TIL and CAR-T Manufacturing (Boosting Success Rates to 95%) with Chantale BernatchezEpisodes 259 - 260: Why Strong Science Isn't Enough to Get Funded: What Investors Actually Look For with Michael RomeConnect with Bilal Fares:LinkedIn: www.linkedin.com/in/b-fares AzureCell website: www.azurecell.co Email: [email protected] the show

Transplant iPSC-derived neurons into a Parkinson's brain and 97% die before they can restore function. Of the 3% that survive, most face the same pathogenic environment that killed the original neurons. This is the compounded biology and CMC problem defining CNS cell therapy today.Bilal Fares, neuroscience entrepreneur and co-founder of AzureCell, is translating a University of Geneva discovery into a genetically engineered iPSC platform built to solve it: neurons that don't just replace what Parkinson's destroyed, but survive the fire that destroyed them.Topics discussed:Why Bilal believes cell therapy is the future of medicine for brain diseases, and the limitations of other approaches (03:06)Bilal’s personal story and the events that guided his commitment to Parkinson’s research and entrepreneurship (04:03)How cell therapy might move beyond simply replacing lost neurons—using engineered cells to produce therapeutics directly in the brain (09:05)The neuroprotective technology AzureCell is developing, designed to shield transplanted neurons from Parkinson’s disease mechanisms (11:31)The platform approach: combining stem cell technologies, genetic engineering, and allogeneic off-the-shelf cell banks (12:38)Why the blood-brain barrier makes cell therapy a necessary approach for certain conditions (13:26)The current status of Azure’s preclinical and manufacturing development, and their plans for clinical translation (14:31)Why previous therapies for Parkinson’s have fallen short, and how cell therapy might sidestep these limitations (15:57)The potential and challenges of using cell therapy for other brain diseases like Alzheimer’s (18:26)Smart insight: The next generation of CNS cell therapy isn't only about neuron replacement. Bilal's thesis reframes transplanted cells as engineered biological factories inside the brain: producing neuroprotective proteins, modulating disease mechanisms in real time, and eventually enabling preventative treatment as manufacturing costs fall and safety matures.If you enjoyed this, check out these episodes on cell therapy, where engineered cells can survive and do more than replace what's lost: Michael Rome's investor lens rounds it out for founders facing the same funding realities.Episodes 269 - 270: How to Turn Mesenchymal Stem Cells into Programmable Cancer Delivery Vehicles with Jun Yung WooEpisodes 253 - 254: How to Source, Manufacture, and Scale the Earliest Stem Cells for Allogeneic Cell Therapy Without Ethical Barriers with Yuta LeeEpisodes 249 - 250: How T Cell Activation Redefines TIL and CAR-T Manufacturing (Boosting Success Rates to 95%) with Chantale BernatchezEpisodes 259 - 260: Why Strong Science Isn't Enough to Get Funded: What Investors Actually Look For with Michael RomeConnect with Bilal Fares:LinkedIn: www.linkedin.com/in/b-fares AzureCell website: www.azurecell.co Email: [email protected] the show

How much of your research lives and dies on the bench? Not because the idea isn’t sound, but because building reproducible, scalable biomaterials remains an unsolved puzzle.Jan Hunik and Matt Baker from MosaMatrix discuss the practical challenges and lessons learned from spinning out a biomaterials company from academia. They explore the importance of quality standards in biotech startups, building a team with complementary skills, and the realities of developing reproducible 3D culture systems for modern research.Topics discussed:The critical gap between invention and reliable biomaterial products (00:40)Building company culture around quality standards from day one (02:45)Balancing scientific curiosity and business direction as co-founders (03:51)The impact of university partnerships on early-stage company development (06:02)Funding challenges and strategies for sustaining a biotech startup (06:47)Advice for scientists on addressing real market needs versus pushing technology (07:50)The importance of listening to customers and investors to find product-market fit (09:19)Vision for scaling technology and breaking even in the next two to three years (10:06)New frontiers in engineering living materials and animal-free biomaterials (12:04)Smart insight: The MosaMatrix team believes good materials are key to unlocking advances in drug discovery, cellular agriculture, and engineered living materials. Their story is a testament to how integrating rigorous science, business discipline, and a razor focus on real-world needs can create the foundation for lasting innovation in biotech.If this conversation got you thinking about biomaterials, scale-out manufacturing, and what it takes to turn a chemistry breakthrough into a fundable company, these episodes explore the same ground from complementary angles.Episodes 221 - 222: From 2D Cultures to Advanced 3D Cell Models for Preclinical Research with Catarina BritoEpisodes 259 - 260: Why Strong Science Isn't Enough to Get Funded: What Investors Actually Look For with Michael RomeEpisodes 265 - 266: From Human Variability to Automated Precision: Accelerating Cell and Gene Therapy Manufacturing Scale-Out with Farlan VeraitchEpisodes 223 - 224: From Cultivated Meat to Chocolate: Rethinking Cellular Agriculture Scale-Up with Steven LangConnect with Jan Hunik and Matt Baker:Emails: [email protected] and [email protected]: www.mosamatrix.comLinkedIn Jan Hunik: www.linkedin.com/in/jan-hunik-0183734LinkedIn Matt Baker: www.linkedin.com/in/matthew-baker-0abb981bSupport the show

What if the real obstacle in 3D cell culture and tissue engineering isn't the cells, but the very ground they grow on?For years, cell culture has relied on flat plastic and passive scaffolds. But biology doesn't happen on a petri dish—cells live in three dimensions, surrounded by a dynamic environment that talks back, adapts, and shapes development in ways static gels simply cannot.That's the premise behind MosaMatrix, a novel hydrogel platform designed to transform how we grow cells, engineer tissues, and screen new drugs created by CEO Jan Hunik and CTO Matt Baker.Topics discussed:Why traditional flat, 2D cell culture misses the biological mark and what a responsive cell environment really looks like (00:27)The origins of MosaMatrix and the realization that new, adaptive hydrogels were needed for dynamic cell culture (04:45)What makes the MosaMatrix hydrogel different—and why passive scaffolds fall short (06:12)Mechanical and biological characteristics that define hydrogel performance, from stiffness to stress relaxation (07:48)The company's pivot from 3D tissue printing to focusing on high-throughput 3D cell culture for drug discovery (08:42)Advantages of a non-animal-derived, reproducible matrix for research and industry (10:20)Strategies for obtaining real-world customer feedback and working in consortia with academia and industry partners (11:51)Key hurdles in quality control, reproducibility, and measuring success in the emerging field (16:05)Challenges with standardizing organoids and the move to smaller, more automatable culture systems (17:50)The impact of automation and data consistency for scaling up 3D cell culture (18:14)Smart insight: MosaMatrix validates its hydrogel not through internal R&D alone, but through direct collaboration with academic and industry partners — testing performance across cell types and culture media. This includes a ~50-company consortium building next-gen 3D cell culture tools and a new consortium improving kidney dialysis with living human cells. The partnerships surface real variables, like how much culture media composition affects results, that continually shape product development.If this conversation got you thinking about biomaterials, scale-out manufacturing, and what it takes to turn a chemistry breakthrough into a fundable company, these episodes explore the same ground from complementary angles.Episodes 221 - 222: From 2D Cultures to Advanced 3D Cell Models for Preclinical Research with Catarina BritoEpisodes 259 - 260: Why Strong Science Isn't Enough to Get Funded: What Investors Actually Look For with Michael RomeEpisodes 265 - 266: From Human Variability to Automated Precision: Accelerating Cell and Gene Therapy Manufacturing Scale-Out with Farlan VeraitchEpisodes 223 - 224: From Cultivated Meat to Chocolate: Rethinking Cellular Agriculture Scale-Up with Steven LangConnect with Jan Hunik and Matt Baker:Emails: [email protected] and [email protected]: www.mosamatrix.comLinkedIn Jan Hunik: www.linkedin.com/in/jan-hunik-0183734LinkedIn Matt Baker: www.linkedin.com/in/matthew-baker-0abb981bSupport the show

In the biotech industry, advancing cell-based therapies is not just about innovation. It's about solving real gaps where conventional treatments fall short, especially against complex, aggressive tumors.In this episode of the Smart Biotech Scientist Podcast, host David Brühlmann welcomes Jun Yung Woo, Co-Founder of AGEM Bio, who offers an in-depth look at the science and strategy behind engineered mesenchymal stem cells (MSCs), with a focus on why glioblastoma is the right proving ground for the platform.Topics discussed:Why glioblastoma is the right Phase I indication: infiltrative growth, immunosuppression, and STING pathway deficiencies that make GBM uniquely suited to the platform (02:43)The surgical workflow: intracavity MSC delivery during tumor resection, oral 5-FC administration, and how engineered cells act as local bioreactors in the resection cavity (04:05)Mechanisms by which engineered MSCs target heterogeneous and invasive tumors through shared vulnerabilities rather than antigen recognition (05:58)Overcoming immune rejection with allogeneic therapies and the unique immunological profile of MSCs (07:32)Manufacturing and scale-up: addressing donor variability, GMP production, and building a reproducible process (09:16)Why GMP manufacturing should be designed in from the earliest stages of research (10:50)Beyond glioblastoma: expanding the platform to other solid tumors, regenerative medicine, and chronic inflammatory disease (11:27)Strategies for international trial expansion and partnerships beyond Singapore (12:41)Reframing MSCs from stem cell therapy to programmable delivery platform: the MSC 2.0 thesis (14:10)Smart insight: The shift Jun Yung articulates is from treating stem cells as the therapy to treating them as programmable therapeutic vehicles. Once you can reliably engineer, manufacture, and preserve their function, the limitation is no longer what the cell naturally does. It becomes what biology you can encode into it. Glioblastoma is the proving ground, and the platform's reach extends to liver cancers, sarcomas, peritoneal malignancies, and chronic inflammatory disease.These episodes expand on the same themes of MSC biology, cell engineering, and the challenges of scaling consistent, functional cell therapies:Episodes 179 - 180 : How Mesenchymal Stromal Cells Are Transforming Care for Diabetes and Autoimmune Diseases with Lindsay DaviesEpisodes 253 - 254: How to Source, Manufacture, and Scale the Earliest Stem Cells for Allogeneic Cell Therapy Without Ethical Barriers with Yuta LeeEpisodes 125 - 126: How to Enhance Cell Engineering Using Mechanical Intracellular Delivery with Armon ShareiEpisodes 129 - 130: Revolutionizing Cell Therapy Manufacturing: Reducing Costs to Reach More Patients with Jason FosterConnect with Jun Yung Woo:LinkedIn: www.linkedin.com/in/junyungwooAGEM Bio website: www.agem.bioEmail: [email protected] the show

What if the answer to solid tumor therapy isn’t about making immune cells smarter—but about rethinking what a therapeutic cell can do For years, mesenchymal stem cells (MSCs) have turned heads for their ability to home in on damaged tissue, yet their clinical utility has lagged behind the hype. What would it take to transform MSCs from passive healers into precision vehicles for next-generation cancer treatment?This week, David Brühlmann sits down with Jun Yung Woo, Co-Founder of AGEM Bio, who’s devoted nearly two decades to decoding and reimagining the potential of MSCs. From engineering stress-resilient cells to pioneering dual-payload therapeutic platforms, Jun Yung Woo bridges fundamental biology and real-world clinical translation.Topics discussed:The case for understanding cell biology before focusing on process scale-up in bioprocessing (02:38)Jun Yung Woo's personal and scientific journey toward developing engineered MSC therapeutics (04:36)How MSCs sense their environment and exert therapeutic effects via secreted factors, rather than tissue replacement (08:28)Key differences between MSC therapies and immune cell therapies like CAR T cells (10:35)Overview of non-viral engineering platforms, and the importance of intracellular trafficking for modifying MSCs (12:23)Design of AGEM Bio's dual-payload MSC product (cytosine deaminase and interferon beta) to induce highly localized tumor stress and immune activation (14:10)Strategies for controlling MSC targeting and minimizing off-target effects, including the use of prodrug activation and localized cell delivery (17:23)Study results from treating companion animals with engineered MSCs, and observations of tumor regression and possible signs of immune memory (20:29)Open questions about the durability of antitumor responses and future directions for clinical research (22:34)Smart insight: Jun Yung Woo challenges the rush toward bioprocess scale-up, arguing that a deeper understanding of cellular biology should come before manufacturing cells at scale. This episode explores how scaling the wrong biology can derail entire therapeutic platforms—and why aligning process development with cellular function may be critical for clinical success.These episodes expand on the same themes of MSC biology, cell engineering, and the challenges of scaling consistent, functional cell therapies:Episodes 179 - 180 : How Mesenchymal Stromal Cells Are Transforming Care for Diabetes and Autoimmune Diseases with Lindsay DaviesEpisodes 253 - 254: How to Source, Manufacture, and Scale the Earliest Stem Cells for Allogeneic Cell Therapy Without Ethical Barriers with Yuta LeeEpisodes 125 - 126: How to Enhance Cell Engineering Using Mechanical Intracellular Delivery with Armon ShareiEpisodes 129 - 130: Revolutionizing Cell Therapy Manufacturing: Reducing Costs to Reach More Patients with Jason FosterConnect with Jun Yung Woo:LinkedIn: www.linkedin.com/in/junyungwooAGEM Bio website: www.agem.bioEmail: [email protected] the show

Why does life-saving insulin cost hundreds of dollars a month for patients, when manufacturing costs are just a fraction of that price? What if the nonprofit model could change everything for affordable access?In the pharmaceutical industry, affordability and access remain two of the biggest hurdles for patients, especially when the economics of essential medicines seem stacked against them.Eric Moyal, founder of Project Insulin, is rewriting the rules of biosimilar development. Coming from a fundraising and nonprofit background rather than the pharma inside track, Eric built Project Insulin not to chase profits, but to deliver an essential therapy at a price real people can afford.Topics covered:Key differences between nonprofit and for-profit models in biotech, especially around fundraising, incentives, and revenue (00:02)The intricate balance between development costs, operating expenses, and setting an affordable price point (00:06)Innovative distribution models to eliminate price inflation by middlemen, including direct-to-patient and clinic partnerships (00:08)Major roadblocks in reinventing drug distribution and the importance of building the right partnerships early on (00:10)Advice for founders and scientists exploring solutions to drug affordability, including corporate structure, fundraising, and perseverance (00:12)Lessons learned after five years building Project Insulin, emphasizing the value of assembling the right team and listening to feedback (00:13)Realistic expectations for Project Insulin’s next five years and the primary goals on the horizon (00:16)The broader need for affordable generic drugs and the broken promise of the current patent system (00:17)How to connect with Project Insulin and support its mission (00:18)Smart insight: Generic medicines should be affordable. Ensuring low-cost, accessible generics is essential to restoring the original balance between pharmaceutical innovation and public access, and it requires collective effort beyond any single player.If you enjoyed this episode, you might want to listen to these within a broader set of discussions on biologics affordability, CMC strategy, and bioprocessing realities — from the economic barriers blocking patient access and regulatory decision-making for biosimilars, to CDMO selection for resource-constrained teams:Episode 136: 5 Roadblocks to Affordable Biologics (And How to Overcome Them)Episodes 57 - 58: Crafting a Solid CMC Strategy: Key Factors and Common Pitfalls with Matthias MüllnerEpisodes 103 - 104: One-Stop Shop vs. Specialist CDMO: A Scientist's Guide to CDMO Selection with Sigma MostafaConnect with Eric Moyal:Email: [email protected]: www.projectinsulin.orgInstagram: www.instagram.com/projectinsulinLinkedIn: www.linkedin.com/company/82500193TikTok: www.tiktok.com/@project.insulinYouTube: www.youtube.com/@ProjectInsulinNext step: If you enjoyed this episode, please leave a review on Apple Podcasts or your favorite podcast platform. By doing so, we can empower more scientists like you. Stay tuned for more inspiring biotech insights in our next episode.Support the show

Insulin was first discovered over a century ago—yet in the United States, 1 in 5 insulin-dependent patients still ration their lifesaving supply. Why is a molecule so essential, and so well understood, still so out of reach for so many?Eric Moyal, founder of Project Insulin, decided to challenge not just the science, but the business model itself. With a background in nonprofit fundraising—not drug development—he’s building a biosimilar insulin glargine and promising to sell it directly to patients at cost, insurance or not.Topics discussed include:The origins of the insulin affordability crisis and the impact of profit-driven healthcare systems (04:27)How over a million Americans are forced to ration their insulin every month, and the broader impact on patients’ (lives 06:37)The advantages and challenges of approaching drug development with a background outside of biotech (08:37)The fundraising-focused strategy for overcoming scientific and technical hurdles in developing biosimilar insulin (09:17)Technical details on Project Insulin’s development process, including selection of CDMOs, importance of analytical data, and process challenges like reverse-phase cleaving and crystallization (11:16)The impact of recent FDA regulatory changes on the development and approval pathway for biosimilars in the U.S. (15:45)Smart insight: A nonprofit approach to essential medicines could reshape the future for patients who depend on them. By removing shareholder expectations and focusing on affordability and access, leaders like Eric Moyal are proving new paths are possible—not through incremental science alone, but through bold re-imaginings of how science serves the public.If you enjoyed this episode, you might want to listen to these within a broader set of discussions on biologics affordability, CMC strategy, and bioprocessing realities — from the economic barriers blocking patient access and regulatory decision-making for biosimilars, to CDMO selection for resource-constrained teams:Episode 136: 5 Roadblocks to Affordable Biologics (And How to Overcome Them)Episodes 57 - 58: Crafting a Solid CMC Strategy: Key Factors and Common Pitfalls with Matthias MüllnerEpisodes 103 - 104: One-Stop Shop vs. Specialist CDMO: A Scientist's Guide to CDMO Selection with Sigma MostafaConnect with Eric Moyal:Email: [email protected]: www.projectinsulin.orgInstagram: www.instagram.com/projectinsulinLinkedIn: www.linkedin.com/company/82500193TikTok: www.tiktok.com/@project.insulinYouTube: www.youtube.com/@ProjectInsulinNext step: If you enjoyed this episode, please leave a review on Apple Podcasts or your favorite podcast platform. By doing so, we can empower more scientists like you. Stay tuned for more inspiring biotech insights in our next episode.Support the show

The cell and gene therapy industry faces massive hurdles—cost, scalability, and the need for highly skilled operators have historically limited the reach of these transformative treatments. advanced therapy medicinal products manufacturing innovation is urgently needed to overcome these challenges and unlock broader global access.Farlan Veraitch, founder and Chief Scientific Officer at Ori Biotech, is leading the way in reimagining manufacturing platforms using automation, modularity, and digital transformation. His vision is redefining how cell and gene therapies are produced—from research labs to point-of-care hospital settings.What’s inside:The use and adaptation of the paper pull tab sterile connection system—miniaturized and multiplexed—to ensure reliable material transfer in the manufacturing process (06:36)How modular and stackable system design supports scale-up and scale-out, increasing manufacturing capacity and flexibility (09:17)Full digitization of the Ori platform, including setting up digital twins, integrating sample prep automation, and capturing data for QA/QC in real time (10:11)Deskilling bioprocess operations, reducing the need for highly trained cell culture staff, and enabling broader use in both centralized facilities and hospitals (14:02)The logistical benefits of separating material prep (like buffer and virus formulation) from the manufacturing site to streamline point-of-care applications (15:39)Farlan’s vision for an accessible, profitable, globally distributed manufacturing platform to support new treatment pipelines (17:14)Driving down cost and improving scalability as key challenges to unlocking the potential of cell and gene therapies (18:49)Strategic insight:The cell and gene therapy field needs to lower manufacturing costs and increase production. Focused, practical approaches are required to make these life-changing therapies more efficient, scalable, and accessible to more patients around the world.Listen for practical perspectives on automation, digital tools, manufacturing infrastructure, and the future possibilities for decentralized, scalable cell and gene therapy production.Connect with Farlan Veraitch:LinkedIn: www.linkedin.com/in/farlan-singh-veraitch-a677112Email: [email protected] Biotech: www.oribiotech.comNext step:Need fast CMC guidance? → Get rapid CMC decision support hereSupport the show

What if the simple act of opening an incubator could undermine the consistency of your cell therapy manufacturing process? Unlike traditional biologics, the moment cells leave their incubator, subtle shifts in temperature, CO₂, and pH can spiral into mission-critical variability, jeopardizing everything from product yield to therapeutic potency.This episode features Farlan Veraitch, founder and Chief Scientific Officer of Ori Biotech. Trained at UCL’s Department of Biochemical Engineering, Farlan blends a bioprocess engineer’s mindset with hands-on experience scaling monoclonal antibodies, before pioneering the first-ever automation platform for embryonic stem cell culture. His drive for eliminating variability and designing systems that scale seamlessly from bench to bedside has informed ORI’s approach to modular cell therapy manufacturing.What you’ll hear in this episode:The importance of controlling pH, temperature, and shear forces in cell therapy manufacturing (00:36)Lessons learned from scaling monoclonal antibody production and its impact on biotech business models (05:23)The unique sources of variability in primary and stem cells, and why automation is essential (11:16)Strategies to minimize human-induced variability in sensitive cell cultures (12:59)How exposure to ambient oxygen and CO₂ during manual processing affects cell viability (14:13)The logic behind Ori Biotech’s modular design to solve environmental control issues (19:04)Strategic insight:As cell and gene therapies push boundaries, manufacturing must keep pace with exponentially tighter requirements. Farlan’s journey highlights a universal lesson for scientists and engineers: process control is not just a technicality, but a necessity for reproducible, scalable, and commercially viable therapies.If you’re grappling with process variability or looking for fresh strategies in cell and gene therapy development, this episode offers an inside view from a scientist who’s worked at the intersection of bioprocess, automation, and commercial translation.Connect with Farlan Veraitch:LinkedIn: www.linkedin.com/in/farlan-singh-veraitch-a677112Email: [email protected] Biotech: www.oribiotech.comNext step:Need fast CMC guidance? → Get rapid CMC decision support hereSupport the show

Digital transformation in biotech is no longer just about adopting new tools, it's about building a foundation where automation, data standardization, and AI integration actually lead to real value and long-term success.For today’s episode, David Brühlmann is joined by David Hardy, a leader at Thermo Fisher Scientific. With years spent guiding automation and digital lab transformation projects around the globe, David’s perspective is equal parts pragmatic and visionary. He’s watched automation go from pilot to scale, advised on the messy realities of lab data, and seen firsthand what separates science fiction from science fact in fully connected labs.In this episode:Bottlenecks in lab automation, especially the challenge of scaling data volume and adapting processes (02:26)Differences between machine learning (ML) and generative AI in lab contexts, and why ML remains central to value extraction (04:17)The key requirements for successful AI adoption: quality data, robust data checking processes, and a cyclical approach to model training (05:25)The vision for an AI-enabled, fully connected lab and the role of predictive maintenance and data quality checks (07:24)Data governance strategies: balancing access and security, and the case for data democratization within organizations (09:32)How data standardization paves the way for better AI and smoother connectivity (11:25)The necessity of treating digital transformation as an ongoing journey, not a one-time project (12:15)Smart insight: digital transformation is not a one-off project but a long-term journey. The most important takeaway for any scientist or leader? Prioritize good quality, standardized data; invest in the foundational work; and foster a culture of collaboration and learning.The connectivity problem doesn't stop at the data layer. These episodes tackle the automation failures, digital infrastructure decisions, and AI readiness questions that determine whether your lab's data ever becomes an asset.Episodes 215 - 216: From Data Silos to Autonomous Biomanufacturing: Digital Twins and AI-Driven Scale-Up with Ilya BurkovEpisodes 233 - 234: Why Most Bioprocess Automation Projects Fail Before the Robot Is Even Ordered with Anthony CatacchioEpisodes 153 - 154: The Future of Bioprocessing: Industry 4.0, Digital Twins, and Continuous Manufacturing Strategies with Tiago MatosEpisodes 17 - 18: How Extracting Gold From Your Data Accelerates Process Development with Ioscani Jiménez del Val - Part 1Connect with David Hardy: LinkedIn: www.linkedin.com/in/david-hardy-46331823 Thermo Fisher Scientific website: www.thermofisher.comNext: If you enjoyed this episode, please leave a review on Apple Podcasts or your favorite podcast platform. By doing so, we can empower more scientists like you. Stay tuned for more inspiring biotech insights in our next episode.Support the show

Despite cutting-edge equipment and brilliant minds, biotech labs often find half their data trapped in difficult-to-access spreadsheets or isolated in silos, making true digital transformation a major, industry-wide hurdle.David Hardy, a leading market and innovation strategist at Thermo Fisher Scientific with 25 years of experience at the intersection of data, automation, and laboratory science, is helping organizations bridge the gap between data chaos and actionable insight.Topics discussed:David Hardy’s early experiences managing NMR data at AstraZeneca and the origins of his interest in data management (03:46)Lessons from retail analytics and returning to scientific data challenges (05:21)Identifying the persistent problem of data connectivity in labs, despite growing data volumes and new technologies (06:40)The most common pushbacks to digital solutions: long-term commitment and culture change (07:38)What mindsets and leadership approaches support successful digital transformation (08:43)Recognizing fragmentation and spotting “hidden” data silos in biotech labs (10:06)Where data fragmentation hurts the most—especially for cross-disciplinary questions and CMC reporting (11:06)Build vs. buy: deciding whether to create in-house digital tools or work with external vendors (13:50)The importance of adaptable systems and preparing for inevitable change in biotech data management (14:43)Smart insight: True digital transformation is not a project, but a process—a way of working that requires vision, patience, and continual adaptation. The labs that break down data silos and connect their digital resources are better positioned to unlock the full promise of biotech: faster discoveries, more robust compliance, and therapies delivered to patients without unnecessary delay.The connectivity problem doesn't stop at the data layer. These episodes tackle the automation failures, digital infrastructure decisions, and AI readiness questions that determine whether your lab's data ever becomes an asset.Episodes 215 - 216: From Data Silos to Autonomous Biomanufacturing: Digital Twins and AI-Driven Scale-Up with Ilya BurkovEpisodes 233 - 234: Why Most Bioprocess Automation Projects Fail Before the Robot Is Even Ordered with Anthony CatacchioEpisodes 153 - 154: The Future of Bioprocessing: Industry 4.0, Digital Twins, and Continuous Manufacturing Strategies with Tiago MatosEpisodes 17 - 18: How Extracting Gold From Your Data Accelerates Process Development with Ioscani Jiménez del ValConnect with David HardyLinkedIn: www.linkedin.com/in/david-hardy-46331823Thermo Fisher Scientific website: www.thermofisher.comNext step: If you enjoyed this episode, please leave a review on Apple Podcasts or your favorite podcast platform. By doing so, we can empower more scientists like you. Stay tuned for more inspiring biotech insights in our next episode.Support the show

Host David Brühlmann returns for a focused solo episode to provide an honest, data-driven perspective on the evolving landscape of host selection for biologics manufacturing. Building on part one, David reviews five alternative expression platforms and offers a clear, practical framework for scientists navigating host cell decisions today. David Brühlmann moves past simplistic "replacement" narratives to instead examine where each technology, from plant farming to cell-free systems, fits in today’s market and production realities.Key topics discussedWhy asking if a novel host will "replace CHO" is the wrong question for scientists and manufacturers (00:11)Critical dimensions to evaluate: cost structure, speed, and intrinsic product quality (01:20)Review of five alternative platforms with current clinical and regulatory status: Plant farming for speed and decentralization (03:42)Insect cells for VLPs and complex proteins (05:00)Cell-free protein synthesis for ADCs and unique conjugation requirements (06:23)Moss for monoclonal antibodies with distinct glycosylation patterns (07:50)Filamentous fungi for high secretion and thermotolerance (08:47)A practical host selection framework by molecule type and manufacturing context (09:59)Detailed constraints and advantages of each platform, including cost, infrastructure, timeline, and product attributes (10:09)Analysis of silkworm production as a disruptive possibility for future biologics manufacturing (13:09)The evolving toolkit available to bioprocess scientists—and why "CHO replacement" is a distraction from more relevant questions (12:06)Smart insight:The real development over the past decade is that bioprocess scientists now have a credible, validated toolkit of alternatives for specific molecules in specific contexts. The practical implication: know this landscape well enough to ask the right host selection question at program initiation, before you've built months of process development around a platform you chose by default.Here are the episodes referenced:Episodes 163 - 164: How Moss Enables Production of Unproducible Protein Therapeutics with Andreas SchaafEpisodes 141 - 142: How Microalgae Cuts Antibody Costs by 70% and Redefines Biomanufacturing with Muriel BardorEpisodes 235 - 236: Plant-Based Biomanufacturing: How Molecular Farming Produces Biopharmaceuticals in Weeks, Not Months with Waranyoo PhoolcharoenEpisodes 217 - 218: Silkworm Biomanufacturing: From Ancient Silk Production to Phase I Vaccine Trials with Masafumi OsawaEpisodes 229 - 230: Cyanobacteria Biomanufacturing: Achieving Carbon-Neutral Production at Lower Cost Than Fermentation with Tim CorcoranNext:If you enjoyed this episode, please leave a review on Apple Podcasts or your favorite podcast platform. By doing so, we can empower more scientists like you. Stay tuned for more inspiring biotech insights in our next episode.Support the show

In this solo episode, David Brühlmann explores the evolving landscape of biologic manufacturing platforms beyond CHO (Chinese hamster ovary) cells. Drawing from previous interviews with platform pioneers and rigorous data analysis, David examines where established and emerging hosts find their strengths—and their limits—in today’s biomanufacturing environment.Topics DiscussedThe historical dominance of CHO cells and what’s changed in the last decade (00:08)Three critical areas where alternative hosts might outperform CHO: cost, speed, and intrinsic product quality (04:52)Moss as a production platform: regulatory advantages, glycosylation, and oncology antibodies (05:47)Microalgae’s carbon-negative potential and the current 1000-fold yield challenge (08:28)Molecular farming (plant-based production): timelines, case of the Medicago COVID-19 vaccine, and overcoming political—not technical—barriers (10:41)Silkworm-based production: infrastructure cost, individual variability, and progress in vaccines (13:07)Cyanobacteria: promise of photosynthetic biomanufacturing and current limitations for clinical use (15:06)The pattern emerging among all alternative platforms: finding niche advantages rather than universally replacing CHO (18:25)A framework for evaluating novel hosts moving forward (19:14)Part 2 examines whether “Will it replace CHO?” is the right question to be asking at all, and introduces an alternative framework for evaluating the issue more effectively.Smart insight:None of the “novel hosts” are universal CHO replacements. Winners emerge in narrow niches: plant farming for pandemic-scale vaccines, silkworms in veterinary and oral applications, and cyanobacteria as a long-term bet for sustainable production.Here are the episodes referenced:Episodes 163 - 164: How Moss Enables Production of Unproducible Protein Therapeutics with Andreas SchaafEpisodes 141 - 142: How Microalgae Cuts Antibody Costs by 70% and Redefines Biomanufacturing with Muriel BardorEpisodes 235 - 236: Plant-Based Biomanufacturing: How Molecular Farming Produces Biopharmaceuticals in Weeks, Not Months with Waranyoo PhoolcharoenEpisodes 217 - 218: Silkworm Biomanufacturing: From Ancient Silk Production to Phase I Vaccine Trials with Masafumi OsawaEpisodes 229 - 230: Cyanobacteria Biomanufacturing: Achieving Carbon-Neutral Production at Lower Cost Than Fermentation with Tim CorcoranNext:If you enjoyed this episode, please leave a review on Apple Podcasts or your favorite podcast platform. By doing so, we can empower more scientists like you. Stay tuned for more inspiring biotech insights in our next episode.Support the show

Funding novel therapeutics isn’t just “harder than ever”—the rules have changed entirely. The wild rush of capital into early-stage biotech during 2020–2021 gave way to a drought, making investor priorities sharper and startup hurdles higher than most founders realize.Michael Rome, Managing Director at Foresite Capital, joined the Smart Biotech Scientist Podcast to dissect what’s really driving funding decisions today, and what early-stage founders must do to stand out.Key topics discussed:The financial cycle of biotech investment before, during, and after the COVID-19 boom (02:47)Why investors are now focused on clear pathways to approved drugs and how founders should frame their proposals (06:10)The evolving importance of CMC expertise and manufacturing readiness for startups at different stages (07:44)Leadership traits and execution qualities investors appreciate in biotech founders and teams (09:18)Promising scientific and market areas including small molecule oncology, degraders, and heterobifunctional molecules (11:24)Practical advice for founders preparing for fundraising: focusing on unmet medical needs and market analysis (14:55)The impact of recent M&A activity and regulatory challenges at the FDA on the future of biotech investment (16:27)The importance of open communication and collaboration between scientists and investors (18:47)Smart insight: For those preparing their next fundraising push, Michael advised:Start with the end in mind: Outline the unmet need, the clinical and market pathway, and the product vision firstReverse engineer your innovation: Work backwards from market and regulatory needs to inform your technical approach, not the other way around.Frame your business case: Make it obvious to investors how your solution advances value in the ecosystemIf you want to go deeper into the themes from this conversation with Michael Rome—how investors evaluate biotech companies, why CMC and execution matter, and how founders can better frame their science for funding—these episodes are a strong next listen:Episodes 189 - 190: Why Smart Biotech Founders Plan CMC First (While Competitors Burn Cash Later)Episodes 165 - 166: Why Your Funding Pitches Fail Despite Brilliant Science (And How to Fix It)Episodes 183 - 184: From Lab to Market: Secrets to Commercializing Cutting-Edge Biotech Innovations with Chervee HoEpisodes 231 - 232: From IND to BLA: The Biologics CMC Decisions That Determine Regulatory Success with Henri KornmannConnect with Michael Rome: LinkedIn: https://www.linkedin.com/in/michael-rome-5067616b/ Foresite Capital website: www.foresitecapital.comNext: If you enjoyed this episode, please leave a review on Apple Podcasts or your favorite podcast platform. By doing so, we can empower more scientists like you. Stay tuned for more inspiring biotech insights in our next episode.Support the show

Strong science alone won’t get your biotech startup funded—investors are sizing up much more than just your molecule.Michael Rome, who leads therapeutics investing at Foresite Capital, brings a rare dual lens as both scientist and investor. Having trained as a Caltech biochemist and incubated dozens of biotech companies, he’s seen first-hand how world-class discoveries become market-ready solutions—or get left behind.Topics discussed:Why strong science isn't always enough to secure funding (00:25)Insights on diverse biotech investing strategies, time horizons, and mandate differences between venture firms (02:44)The advantage of Foresite’s multi-stage and cross-sector investment model (03:32)Michael’s journey from science and math enthusiast to biotech investor (04:49)The importance of founding team track records and repeat entrepreneurs in early-stage company building (12:53)The evolving global landscape: company formation, investment, and biotech innovation in Asia (with a focus on China) (15:56)Effects of shifting geopolitical and regulatory landscapes on US, European, and Asian biotech partnerships (20:25)The practicalities and tradeoffs of outsourcing drug development, R&D, and manufacturing overseas (22:04)Smart insight: Engage with investor perspectives early: align your work to real market needs. Seek partnerships with industry leaders and proven entrepreneurs, embrace global resources, networks, and collaborations to maximize both scientific and commercial potential.If you want to go deeper into the themes from this conversation with Michael Rome—how investors evaluate biotech companies, why CMC and execution matter, and how founders can better frame their science for funding—these episodes are a strong next listen:Episodes 189 - 190: Why Smart Biotech Founders Plan CMC First (While Competitors Burn Cash Later)Episodes 165 - 166: Why Your Funding Pitches Fail Despite Brilliant Science (And How to Fix It)Episodes 183 - 184: From Lab to Market: Secrets to Commercializing Cutting-Edge Biotech Innovations with Chervee HoEpisodes 231 - 232: From IND to BLA: The Biologics CMC Decisions That Determine Regulatory Success with Henri KornmannConnect with Michael Rome: LinkedIn: https://www.linkedin.com/in/michael-rome-5067616b/ Foresite Capital website: www.foresitecapital.comNext: If you enjoyed this episode, please leave a review on Apple Podcasts or your favorite podcast platform. By doing so, we can empower more scientists like you. Stay tuned for more inspiring biotech insights in our next episode.Support the show

What happens between scientific discovery and clinical trials? For too many drug candidates, the answer is “failure”—not because the idea lacked merit, but because the critical handoff between discovery and IND-enabling studies gets overlooked, rushed, or under-resourced.This episode features Milan Tomic, whose journey stretches from nucleic acid chemistry to leading GMP manufacturing and biodefense initiatives with hundreds of millions in US government support. Milan’s focus lies in streamlining drug development, from rapid molecule design to building manufacturing infrastructure, all grounded in holistic, systems-level thinking.Topics discussed:Why so many promising programs fail between discovery and the clinic, and how to close this gap through early, iterative design and testing (02:52)The practical advantages and considerations of cell-free protein synthesis for rapid prototyping and testing during development (07:30)How to decide when to deploy cell-free production versus traditional CHO systems (08:29)Recommendations for resource-constrained startups: what to focus on first and why stability and documentation matter most (10:55)Consistent success factors across Milan’s experiences, from government contract projects to launching his own company (13:54)Candid stories of setbacks and lessons—such as the critical importance of safety in development and the impact of overlooked technical details like facility lighting (15:30)The importance of linking drug design decisions to target patient needs and regulatory considerations, thinking holistically, and using target product profiles to guide development (20:22)Smart insight: Perhaps the most powerful takeaway isn’t technical, but personal. Staying curious, open-minded, and deriving enjoyment from the process is vital for sustaining the drive necessary for biotech’s long and often unpredictable journey. The best way to bridge the valley of death in biotech is through rigorous iterative design, early testing of critical attributes, holistic planning, and a relentless commitment to learning.If you enjoyed this episode you might also like listening to:Episodes 189 - 190 : Why Smart Biotech Founders Plan CMC First (While Competitors Burn Cash Later)Episodes 123 - 124: Manufacturability: Why Most Protein Candidates Fail (And How to Pick Winners Early) with Susan SharfsteinEpisodes 213 - 214: From Developability to Formulation: How In Silico Methods Predict Stability Issues Before the Lab with Giuseppe LicariEpisodes 231 - 232: From IND to BLA: The Biologics CMC Decisions That Determine Regulatory Success with Henri KornmannConnect with Milan Tomic:LinkedIn: www.linkedin.com/in/milan-tomic-phdAlbrem Biopharma: www.albrem.comNext Step:If you enjoyed this episode, please leave a review on Apple Podcasts or your favorite podcast platform. By doing so, we can empower more scientists like you. Stay tuned for more inspiring biotech insights in our next episode.Support the show

The gap between a “drug” and a true “product” is where many therapies fail.Milan Tomic, biotech veteran, GMP manufacturing expert, and founder of Albrem, has spent 30 years turning promising science into scalable, executable products that can actually reach patients. His experience spans everything from antibody development to building large-scale GMP facilities. Today, he helps biotech teams align scientific innovation with the operational and regulatory realities needed for successful commercialization.Topics discussed:Milan’s path from curiosity-driven research in molecular biology to biotech industry leadership (05:24)The importance of integrating work-life factors into career decisions, and balancing scientific depth with operational and business responsibilities (08:22)The unexpected role that salesmanship plays for scientists moving into entrepreneurship (10:40)Lessons from transitioning between scientific disciplines, including dealing with setbacks like unpublished graduate work (12:57)How curiosity led Milan to oversee the redesign of a 2,000-liter GMP manufacturing facility (16:16)Key advice for scientists on process design and scaling up, especially for those involved in CMC (20:18)Smart insight: A promising molecule isn’t enough—successful drug development requires designing early for scalability, GMP compliance, and real patient need. Companies that align science with manufacturability and market fit are far better positioned to advance, attract investors, and secure partners.If you enjoyed this episode you might also like listening to:Episodes 189 - 190 : Why Smart Biotech Founders Plan CMC First (While Competitors Burn Cash Later)Episodes 123 - 124: Manufacturability: Why Most Protein Candidates Fail (And How to Pick Winners Early) with Susan SharfsteinEpisodes 213 - 214: From Developability to Formulation: How In Silico Methods Predict Stability Issues Before the Lab with Giuseppe LicariEpisodes 231 - 232: From IND to BLA: The Biologics CMC Decisions That Determine Regulatory Success with Henri KornmannConnect with Milan Tomic:LinkedIn: www.linkedin.com/in/milan-tomic-phdAlbrem Biopharma: www.albrem.comNext Step:If you enjoyed this episode, please leave a review on Apple Podcasts or your favorite podcast platform. By doing so, we can empower more scientists like you. Stay tuned for more inspiring biotech insights in our next episode.Support the show

The "data lake" that was supposed to unify bioprocessing intelligence has, in most companies, become something else entirely: a data swamp, where information goes in and insight rarely comes back out. For anyone trying to deploy AI in GMP manufacturing, that is not a technical problem. It is the problem.Steffen Kreye has seen it from both sides. As former upstream development lead at Bayer and now Professor of Industrial Biotechnology at Berliner Hochschule für Technik, he brings an unusually grounded perspective on where AI in bioprocessing actually stands, what the next generation of scientists needs to be equipped with, and what industry can do right now to help close the gap.Key topics discussed:How soft skills like teamwork and self-motivation are becoming increasingly important for scientists, and strategies to foster them in education (02:47)The reality behind AI and machine learning in biotech today, including current limitations and the true state of industry adoption (05:48)Envisioning bioprocessing ten years from now: the potential of continuous manufacturing, digital twins, and automation, and the evolving diversity of bioprocesses (08:09)Practical ways industry professionals can support university education—from guest lectures to hands-on lab courses—and why it matters (10:09)Motivating students by connecting coursework to real industry roles and contributions (12:10)The importance of finding and following individual motivation in science careers (12:41)Reflections on moving from industry to academia: autonomy, challenges, and the satisfaction of seeing students grow into scientists (13:22)How strong collaboration between academia and industry leads to better innovation and prepares future scientists for success (15:53)Smart Insight: Most companies talking about AI in bioprocessing are still solving a more fundamental problem: getting their data into a state where AI could use it at all. The breakthrough will not come from the algorithm. It will come from the unglamorous, years-long work of making data accessible, harmonized, and meaningful across sites, systems, and GMP boundaries.Here are some other guests who touched on similar themes:Episodes 175 – 176 : How Virtual Reality Training Solves Europe's Bioproduction Talent Shortage with Sandrine Lemoine — about training the next generation of biopharma talent.Episodes 93 – 94: From Lab Coat to LinkedIn: Benjamin McLeod's Journey to Cell and Gene Therapy Influencer — another career pivot story from a scientist who stepped outside the traditional industry path.Episodes 111 – 112: AI Meets Biology: Why Domain Expertise Still Rules in the Age of Large Language Models with Lars Brandén — very aligned with Steffen's nuanced take that AI is a tool but human expertise in bioprocessing still matters.Connect with Steffen Kreye:LinkedIn: www.linkedin.com/in/steffen-kreye-3b531183/Berliner Hochschule für Technik: www.prof.bht-berlin.de/kreyeNext Step:If you enjoyed this episode, please leave a review on Apple Podcasts or your favorite podcast platform. By doing so, we can empower more scientists like you. Stay tuned for more inspiring biotech insights in our next episode.Support the show

When AI can draft a literature review in minutes, the question bioprocess educators can no longer avoid is this: what does a student actually need to learn?Steffen Kreye has a clear answer. As Professor of Industrial Biotechnology at Berliner Hochschule für Technik, he trains engineers who step into industry ready to run a bioreactor, not just describe one. His argument is direct: hands-on lab competence is the one thing AI cannot replicate, and it is exactly what underfunding is quietly eroding.Topics discussed:Why Steffen Kreye left his lab head role at Bayer to become a professor and how his career evolved (03:54)The unique mission of universities of applied sciences and their close connection to industry needs (11:16)Challenges of delivering lab-based education, including funding and equipment constraints (12:32)Creative strategies for partnering with biotech companies to sustain practical lab courses (14:34)How reading student theses, partnerships, and conferences help Steffen Kreye and his colleagues stay current in a rapidly changing field (17:43)The impact of AI and digital tools on research, teaching methods, and student assessment (21:18)Why traditional theoretical projects are less relevant, and the growing importance of problem-solving and oral examinations (22:09)In Part 2, Steffen gives his unfiltered take on where AI in bioprocessing actually stands, which human capabilities are becoming harder to replace, and what a well-prepared bioprocess engineer will need to look like by 2035.Smart Insight: Once AI can produce a polished report from a well-structured prompt, the only assessment that still reveals genuine understanding is the one a student has to navigate in real time, without a tool to hide behind.Here are some other guests who touched on similar themes:Episodes 175 – 176 : How Virtual Reality Training Solves Europe's Bioproduction Talent Shortage with Sandrine Lemoine — about training the next generation of biopharma talent.Episodes 93 – 94: From Lab Coat to LinkedIn: Benjamin McLeod's Journey to Cell and Gene Therapy Influencer — another career pivot story from a scientist who stepped outside the traditional industry path.Episodes 111 – 112: AI Meets Biology: Why Domain Expertise Still Rules in the Age of Large Language Models with Lars Brandén — very aligned with Steffen's nuanced take that AI is a tool but human expertise in bioprocessing still matters.Connect with Steffen Kreye:LinkedIn: www.linkedin.com/in/steffen-kreye-3b531183/Berliner Hochschule für Technik: www.prof.bht-berlin.de/kreyeNext Step:If you enjoyed this episode, please leave a review on Apple Podcasts or your favorite podcast platform. By doing so, we can empower more scientists like you. Stay tuned for more inspiring biotech insights in our next episode.Support the show

Can aging be fundamentally slowed or even reversed—not by science fiction, but by harnessing the unassuming power of super-early stem cells?In Part 1, Yuta Lee, Founder and CEO of Accelerated Bio, walked through the biology, ethical sourcing, and manufacturing profile of human trophoblast stem cells. In Part 2, the conversation shifts to the larger ambition: using those cells not just to treat disease, but to slow, stop, or reverse biological aging itself. The evidence starts with a striking finding from the National Institute on Aging, and it builds from there.Topics discussed:The science and ethics of sourcing stem cells from ectopic pregnancies (03:02)Differences in differentiation potential between very early-stage cells and traditional MSCs or iPSCs (05:09)The origins of the research focus, driven by NIH/NIA inquiry and lessons from Stanford parabiosis studies (07:27)Explanation of senescent cells, inflammation, and disease connections (08:51)Potential therapeutic scope, from neurodegeneration to autoimmune diseases, and systemic anti-inflammatory applications (09:26)Vision for aging prevention—possibility of maintaining young biological age through regular secretome therapy (10:21)Challenges and global differences in regulation, access, and clinical adoption (12:05)The realistic limits and potential for reversing versus preventing age-related damage (13:20)The future landscape of cell and gene therapy in medicine (14:20)Why more investment is needed in longevity science and therapeutics (16:25)Practical takeaways for listeners about improving healthspan and longevity today (18:07)Smart insight:Prevention is becoming the new frontier of medicine, shifting from treating disease to preserving long-term biological function. Yuta Lee highlights a future where proactive longevity strategies, from lifestyle choices to emerging biotech, could keep us healthier for longer and push toward “escape velocity” against aging.If you’re interested in how we turn living biology into scalable, reliable, off-the-shelf therapies without losing control of the system, explore these episodes:Episodes 105 - 106: From Proteins to Cell Therapy: Why ATMPs Aren't Just Complex Biologics with Oliver KraemerEpisodes 147 - 148: Lab-Grown Blood: How Stem Cells Transform Transfusions with Ari GargirEpisodes 179 - 180: How Mesenchymal Stromal Cells Are Transforming Care for Diabetes and Autoimmune Diseases with Lindsay DaviesEpisodes 211 - 212: When the Innovator Becomes the Patient: Manufacturing Reality vs. Patient Urgency with Jesús ZurdoConnect with Yuta Lee:LinkedIn: www.linkedin.com/in/yuta10Accelerated Bio website: www.acceleratedbio.comNext:If you enjoyed this episode, please leave a review on Apple Podcasts or your favorite podcast platform. By doing so, we can empower more scientists like you. Stay tuned for more inspiring biotech insights in our next episode.Support the show

What if the key to scalable, off-the-shelf cell therapy was hiding in tissue that surgeons discard every day?Yuta Lee, Founder and CEO of Accelerated Bio, has spent two decades building a cell therapy platform on exactly that insight. Human trophoblast stem cells, sourced from ectopic pregnancy tissue that is otherwise discarded, sit at a unique biological intersection: earlier than MSCs, free from the ethical barriers of embryonic stem cells, expandable to 85 population doublings, and naturally equipped with HLA-G immune modulation that opens the door to allogeneic, off-the-shelf therapy at scale.Topics discussedCommon misconceptions and challenges in bioprocess development for biological therapeutics (02:45)The origin story behind Yuta Lee's interest in stem cells, including his father’s surgical discovery (04:15)A look at the intellectual property strategy that protected and enabled Yuta Lee's company to develop its platform (07:26)A clear explanation of different stem cell types (embryonic, trophoblast, mesenchymal, adult, and induced pluripotent) and their sources (09:37)Ethical and regulatory issues involved in sourcing stem cells, and how trophoblast cells offer a unique alternative (10:59)Discussion of stem cell differentiation, population doubling, and scalability for manufacturing purposes (17:03)Importance of immune privilege and HLA-G expression in pre-placental cells for off-the-shelf therapies (20:20)Shifts in the industry from autologous to allogeneic therapies, and the role trophoblast cells may play in future treatments (22:00)In Part 2, Yuta Lee goes into the science of biological aging, the senescent cell secretome findings from the National Institute on Aging, and what a prevention-first therapeutic approach to healthspan extension could look like in practice.Smart insight:The scalability ceiling of MSCs is not just a manufacturing inconvenience, it is a strategic constraint. At 25 to 30 population doublings from birth-derived donors, every new donor batch requires revalidation as a distinct biological starting material. Trophoblast stem cells at 85 doublings from a single donor change that equation fundamentally, making true allogeneic scale not just biologically possible but manufacturable.If you’re interested in how we turn living biology into scalable, reliable, off-the-shelf therapies without losing control of the system, explore these episodes:Episodes 105 - 106: From Proteins to Cell Therapy: Why ATMPs Aren't Just Complex Biologics with Oliver KraemerEpisodes 147 - 148: Lab-Grown Blood: How Stem Cells Transform Transfusions with Ari GargirEpisodes 179 - 180: How Mesenchymal Stromal Cells Are Transforming Care for Diabetes and Autoimmune Diseases with Lindsay DaviesEpisodes 211 - 212: When the Innovator Becomes the Patient: Manufacturing Reality vs. Patient Urgency with Jesús ZurdoConnect with Yuta Lee:LinkedIn: www.linkedin.com/in/yuta10Accelerated Bio website: www.acceleratedbio.comNext:If you enjoyed this episode, please leave a review on Apple Podcasts or your favorite podcast platform. By doing so, we can empower more scientists like you. Stay tuned for more inspiring biotech insights in our next episode.Support the show

Are you still using one-factor-at-a-time experiments for biosimilar development, losing months, missing interactions, and risking costly dead-ends?In this episode, David Brühlmann, host of the Smart Biotech Scientist Podcast, reveals how traditional "one factor at a time" screening in biosimilar development can take over 12 months, while the parallel group design massively accelerates discovery by grouping up to five factors per experiment and applying a multivariate analysis pipeline.Topics discussed:The limitations of traditional and large DoE designs and the advantages of parallel group design (00:08)Best practices for grouping compounds by biological mechanism with four essential rules (00:53)The importance of anchor compounds, separating strong modulators, and initial univariate screens for unknown compounds (01:43)Guidance on managing practical issues, including evaporation, liquid handling, osmolality, and replicating production processes (06:42)The use of multivariate analysis tools: Principal Component Analysis, Mahalanobis distance, and decision trees for candidate selection (10:14)Key results and outcomes from applying the parallel group method, including faster and more cost-effective quality modulator identification (12:46)Three improvements David would recommend today: prequalifying compounds, broader quality analytics, and hybrid modeling integration (13:49)The shift in mindset from “time problem” to “information problem” in process development (16:50)Extending the parallel group and multivariate approach to other areas like clone selection and scale-up decisions (17:52)Smart insight:Process development is fundamentally about generating actionable information, not just running more experiments. The parallel group, multivariate pipeline lets teams ask better questions, in parallel, with dramatically improved data yield. This mindset and methodology extend well beyond biosimilar media development into clone selection, feed design, and process characterization, wherever complexity would paralyze traditional approaches.If you want more detail, you can read the full article “Parallel experimental design and multivariate analysis provides efficient screening of cell culture media supplements to improve biosimilar product quality” published in Biotechnology and Bioengineering, which outlines the methods and findings behind this approach.If you’re interested in hybrid modeling, here’s what previous podcast guests have shared on the topic, offering perspectives from fundamentals to real-world applications.Episodes 05 - 06: Hybrid Modeling: The Key to Smarter Bioprocessing with Michael SokolovEpisodes 99 - 100: From Raw Data to Actionable Insights: Unlocking the Power of Process Models with Fabian FeidlEpisodes 137 - 138: Skip 90% of Bioreactor Runs: The In Silico Revolution in Bioprocess Development with Yossi QuintEpisodes 173 - 174: Mastering Hybrid Model Digital Twins: From Lab Scale to Commercial Bioprocessing with Krist GernaeyNext step: If this was useful, leave a review on Apple Podcasts or Spotify. It helps other scientists find this content, and it genuinely matters.Support the show

Are you stuck screening endless compounds in biosimilar development and still not hitting your quality targets? Efficient compound screening is one of the toughest bottlenecks in biopharma, with outdated methods slowing progress and risking critical quality attributes in monoclonal antibody development.David Brühlmann breaks down a practical, parallel framework for rapid compound screening that addresses interaction effects, masking, and data quality. Methods proven in challenging biosimilar development programs.Topics discussed:The historical bottleneck of one-at-a-time screening in drug discovery and the impact of high throughput methods (01:04)Problems with both one-factor-at-a-time and large design of experiments approaches when handling many variables (02:10)Description of the parallel group method: splitting 17 quality modulating compounds into five biologically relevant groups and running experiments in parallel (06:09)How grouping compounds by biological mechanism improves interpretability and experimental design (06:43)Strategies for minimizing dilution effects, toxicity risks, and masking in multi-factor screens (08:24)The importance of multivariate analysis: using principal component analysis (PCA), Mahalanobis distance, and decision trees to interpret and select optimal experimental conditions (10:31)Real-world outcomes: identifying optimal compound combinations in just two rounds of screening (15:20)Reflections on the evolving role of hybrid modeling and machine learning in biosimilar process optimization (15:54)In Part 2, the focus shifts to a hands-on approach, covering how to design compound groups based on biology, set concentration ranges without compromising data quality, and execute a 96-well screen with the rigor the method demands. It also highlights three key aspects that would be approached differently if the study were conducted today.Strategic insight:Effective compound screening shifts from one-at-a-time testing to biology-driven parallel grouping combined with multivariate analytics, enabling faster identification of optimal combinations while preserving data quality and capturing interaction effects.If you want more detail, you can read the full article “Parallel experimental design and multivariate analysis provides efficient screening of cell culture media supplements to improve biosimilar product quality” published in Biotechnology and Bioengineering, which outlines the methods and findings behind this approach.If you’re interested in hybrid modeling, here’s what previous podcast guests have shared on the topic, offering perspectives from fundamentals to real-world applications.Episodes 05 - 06: Hybrid Modeling: The Key to Smarter Bioprocessing with Michael SokolovEpisodes 99 - 100: From Raw Data to Actionable Insights: Unlocking the Power of Process Models with Fabian FeidlEpisodes 137 - 138: Skip 90% of Bioreactor Runs: The In Silico Revolution in Bioprocess Development with Yossi QuintEpisodes 173 - 174: Mastering Hybrid Model Digital Twins: From Lab Scale to Commercial Bioprocessing with Krist GernaeyNext step: If this was useful, leave a review on Apple Podcasts or Spotify. It helps other scientists find this content, and it genuinely matters.Support the show

When every batch belongs to a single patient, a single centralized facility cannot serve the world. In Part 2, Chantale Bernatchez moves from process development into the broader consequences of that reality: the manufacturing model built around clinical proximity, the global alliance bringing TIL production to regions with no current access, and the next-generation engineered approaches redefining what these therapies can do.Chantale Bernatchez is Head of Process Development at CTMC, a joint venture between Resilience and MD Anderson Cancer Center. If you missed Part 1, she explained how specific activation changes recovered a failing TIL process from 50% to 95% success in heavily pre-treated patients.Topics discussed:How close collaboration with MD Anderson accelerates clinical development and regulatory readiness (03:08)CTMC’s approach to process development and adapting to innovative technologies (05:15)The value of partnership-based models versus traditional CDMO-driven approaches (06:24)Global technology transfer: building alliances to expand access to cell therapies, with a case study in Brazil (07:35)Key barriers and solutions for cell therapy manufacturing in new regions (09:41)Practical advice for scientists starting in GMP manufacturing and process development (10:46)Future directions in CAR T and TIL, including logic-gated CARs, engineered TILs, and in vivo therapies (12:24)The importance of continued innovation and collaboration to expand global patient access (17:39)Smart insight:The choice of manufacturing partner in cell therapy is not a logistics decision. It is a process development decision. CTMC's collaboration-based model exists because many early-stage developers arrive without a process robust enough to hand over. For scientists in small or mid-sized companies, engaging that kind of partnership too late, or on purely transactional terms, is one of the most avoidable risks in early clinical development.If you’re interested in exploring further the concepts we touched on, such as cell therapy manufacturing, process control, and scaling living therapies—take a look at these related discussions:Episodes 125 - 126: How to Enhance Cell Engineering Using Mechanical Intracellular Delivery with Armon ShareiEpisodes 109 - 110: Spinning Like Earth: Designing Low-Shear Bioreactors for Better Cell Culture with Olivier DetournayEpisodes 105 - 106: From Proteins to Cell Therapy: Why ATMPs Aren’t Just Complex Biologics with Oliver KraemerConnect with Chantale Bernatchez:LinkedIn: www.linkedin.com/in/chantale-bernatchez-22b09511CTMC website: www.ctmc.comSupport the show

The most underappreciated parameter in cell therapy process development is not your bioreactor, your media, or your activation protocol. It is the patient. Chantale Bernatchez has spent 20 years learning that lesson the hard way, watching the same manufacturing process succeed brilliantly with one donor and fail completely with the next. In this episode, she explains why starting material variability is the defining challenge of cell therapy manufacturing, and what it actually takes to build a process robust enough to survive it.Chantale Bernatchez is Head of Process Development at CTMC, a joint venture between Resilience and MD Anderson Cancer Center. She holds a PhD in immunology and has spent two decades advancing T cell therapy from early research programs at MD Anderson to GMP-compliant clinical manufacturing. She holds four patents in adoptive cell therapy.Key topics discussed:Personal journey: from immunology PhD in Quebec to cell therapy leadership in Houston (04:25)Evolution of TIL therapy at MD Anderson, including manufacturing innovations to overcome declining T cell yields (06:14)The fundamental differences between traditional medicines and cell-based immunotherapies (10:01)Unique manufacturing complexities for autologous therapies, including batch variability and process standardization (11:19)Strategies to address decreased cell fitness in heavily pretreated patients, including changes in cell activation and culture conditions (13:57)Key learnings from the CAR T and TIL manufacturing process: balancing process duration, cell fitness, and product yield (16:28)Mechanistic differences between CAR T and TIL therapies and their implications for efficacy and resistance (17:58)The limits and risks of automation in cell therapy manufacturing—balancing manual vs. automated processes (24:04)Why moving between manufacturing platforms raises challenges in comparability and clinical outcomes (25:44)The ongoing search for critical cell quality attributes that correlate with patient response (27:00)In part two, Chantale goes deeper into next-generation approaches, technology transfer, and what needs to change to broadly expand patient access.Smart insight: In cell therapy, manufacturing isn’t just a production step. It defines the therapy itself. Because each patient’s starting cells are unique, even subtle changes in the process can significantly alter clinical outcomes.If you’re interested in exploring further the concepts we touched on—such as cell therapy manufacturing, process control, and scaling living therapies—take a look at these related discussions:Episodes 125 - 126: How to Enhance Cell Engineering Using Mechanical Intracellular Delivery with Armon ShareiEpisodes 109 - 110: Spinning Like Earth: Designing Low-Shear Bioreactors for Better Cell Culture with Olivier DetournayEpisodes 105 - 106: From Proteins to Cell Therapy: Why ATMPs Aren’t Just Complex Biologics with Oliver KraemerConnect with Chantale Bernatchez:LinkedIn: www.linkedin.com/in/chantale-bernatchez-22b09511CTMC website: www.ctmc.comSupport the show

Getting an NDA signed shouldn't take weeks. If your CRO needs more than 48 hours to start the paperwork, your project timeline is already moving in the wrong direction.Ron Najafi knows what rigorous analytical work actually looks like under pressure. As founder and CEO of Emery Pharma, he led the investigation that identified NDMA as a degradation product of ranitidine — findings the FDA formally validated and that reshaped how the industry approaches nitrosamine risk assessment. In Part 2, he moves from that scientific foundation into the operational questions that determine whether a CRO partnership accelerates your program or quietly slows it down.If you haven't heard Part 1, it covers Ron's career arc and the technical details of nitrosamine contamination in pharmaceutical development. This episode stands on its own for anyone focused on CRO selection, bioanalytical strategy, and what three decades of building analytical companies actually teaches you.Topics discussed:How to tell if a CRO’s workflow is robust—or just rigid (05:51)The importance of method validation and product stability testing (07:27)Managing expectations and trust-building in client relationships (08:29)Entrepreneurial lessons: raising capital, team-building, and finding the right partners (10:00)The hidden costs of public vs. private biotech ventures (12:31)Reducing bioanalytical costs in biologics through mass spectrometry (13:23)The future of analytical workflows and personalized medicine (14:48)Smart insight:In biotech, success isn’t just about the science—it’s about strategic discipline. Ron emphasizes a few hard-earned principles: raise more capital than you think you’ll need, don’t fixate on valuation, and invest in smart, creative talent. Just as important, real value is unlocked through strong partnerships and the ability to manage collaborations and acquisitions with intention.If this topic resonates with you, here are a few related episodes on building strong CMC foundations and avoiding costly development mistakes:Episodes 231 - 232: From IND to BLA: The Biologics CMC Decisions That Determine Regulatory Success with Henri KornmannEpisodes 203 - 204: Mastering CRO Selection: Essential Questions for CMC Analytical Development with Daniel GalbraithEpisodes 199 - 200: Mastering Quality by Design: From Product Failures to Commercial Success in Biologics CMC DevelopmentEpisodes 189 - 190: Why Smart Biotech Founders Plan CMC First (While Competitors Burn Cash Later)Episodes 139 - 140: Regulatory Secrets Revealed: Why Your CMC Strategy Could Make or Break Your Biotech Startup with Rivka ZaibelEpisodes 57 - 58: Crafting a Solid CMC Strategy: Key Factors and Common Pitfalls with Matthias MüllnerEpisodes 23 - 24: Strategies for Success: Master CMC Development with Gene LeeConnect with Ron Najafi:LinkedIn: www.linkedin.com/in/ronnajafiEmery Pharma: www.emerypharma.comSupport the show

When drug safety fails, patients and entire markets pay the price. Understanding your CMC isn't just compliance — it's the line between therapeutic promise and product recall.Ron Najafi has lived that reality firsthand. As founder of NovaBay Pharmaceuticals and Emery Pharma, he spent decades building companies at the intersection of analytical chemistry and drug development. His investigation into nitrosamine contamination in ranitidine — which led the FDA to formally validate Emery Pharma's findings — remains one of the most consequential episodes in recent pharmaceutical quality history.In Part 1, Ron traces the scientific and entrepreneurial path that led him there, and shares what CMC teams working in drug development need to understand about impurity risk before it becomes a regulatory crisis.Episode highlights:Early academic experiences and inspirations that Ron Najafi to a science career (05:46)Challenges and milestones in building companies like CP Lab Safety and NovaBay Pharmaceuticals (07:59)The invention and impact of the ECO Funnel® on lab safety and environmental responsibility (12:01)The formation of Emery Pharma following industry setbacks and lessons in adaptation (17:03)The fundamentals of impurity risk analysis, especially nitrosamine contamination in pharmaceuticals (20:56)The ranitidine (Zantac) NDMA discovery, its investigation, and consequences for drug regulation (23:33)Common sources of nitrosamine and practical advice for bioprocess risk management (27:51)Differences in impurity risk between small molecule and biologic drug processes (28:03)The necessity and regulatory expectation of impurity and leachable/extractable analysis (30:07)Smart insight:One of Ron's clients conducted a superficial nitrosamine risk assessment, proceeded to manufacturing, and spent approximately $6 million producing three batches. At final FDA-required testing, NDMA came back at 11,000 nanograms per pill against an acceptable daily intake limit of 96 nanograms. The batches were unusable.A thorough risk assessment run earlier would have cost a fraction of that. If you are developing a drug with secondary or tertiary amines in your process and have not yet conducted a formal nitrosamine risk assessment, that is the one action to take after listening to this episode.If this topic resonates with you, here are a few related episodes on building strong CMC foundations and avoiding costly development mistakes:Episodes 231 - 232: From IND to BLA: The Biologics CMC Decisions That Determine Regulatory Success with Henri KornmannEpisodes 203 - 204: Mastering CRO Selection: Essential Questions for CMC Analytical Development with Daniel GalbraithEpisodes 199 - 200: Mastering Quality by Design: From Product Failures to Commercial Success in Biologics CMC DevelopmentEpisodes 189 - 190: Why Smart Biotech Founders Plan CMC First (While Competitors Burn Cash Later)Episodes 57 - 58: Crafting a Solid CMC Strategy: Key Factors and Common Pitfalls with Matthias MüllnerEpisodes 23 - 24: Strategies for Success: Master CMC Development with Gene LeeConnect with Ron Najafi:LinkedIn: www.linkedin.com/in/ronnajafiEmery Pharma: www.emerypharma.comSupport the show

Shear sensitivity is the silent challenge behind many advanced biomanufacturing modalities. Orbital-shaken bioreactors—often underestimated—may be a key enabler your CMC development is missing.Tibor Anderlei, CSO at Kühner Shaker, joined David Brühlmann on the Smart Biotech Scientist Podcast to unpack the hidden physics behind bioprocess reproducibility and next-generation shaking technology. He has seen firsthand how overlooking fundamental parameters can derail scale-up and delay development timelines. In his role, Tibor is responsible for the customer interface—spanning sales, service, support, GMP topics, troubleshooting, marketing, and applied technology—with a focus on orbital shaking technology and small-scale cultivation support.Topics discussed:The importance of measuring oxygen transfer rate (OTR) and carbon dioxide transfer rate (CTR) for reproducible bioprocesses—why DO is not sufficient (02:55)Real-time process analytical technology (PAT) for small-scale bioreactors, including microtiter plates and shake flasks (06:47)Pre-culture reproducibility: transferring at the right OTR and its impact on main cultures (07:56)Price sensitivity and scale-up challenges in cultivated meat—implications for media and equipment selection (10:36)Expansion of shaking technology to fields such as mixing, storage, and thawing, including applications in liquid crystal production (12:10)Leadership lessons from competing with bigger players: how smaller companies stay innovative, agile, and close to their customers (14:20)The significance of strong business partner relationships and trusting gut feeling in decision-making (16:32)Key advice for smart biotech scientists: careful definition of screening conditions and the use of online measurement tools at small scale (18:09)Accessible resources for mastering shaken bioreactor techniques, including webinars and direct contact with Tibor Anderlei (19:38)Smart insight:Treat small-scale shaken systems as real bioreactors and define screening conditions carefully from the start. Using online measurement tools even at early stages provides critical visibility and helps ensure that results are reproducible and scalable.Building a robust scale-up strategy requires looking at the process from multiple angles—regulatory, digital, and operational. Listen to those previous episodes:Episode 03 - 04: How to Master Biotech Scale-up Without Guesswork with Leonardo SibilioEpisode 25 - 26: 9 Critical Steps for a Seamless Transition to Large-Scale ProductionEpisode 231-232: From IND to BLA: The Biologics CMC Decisions That Determine Regulatory Success with Henri KornmannEpisode 233-234: Why Most Bioprocess Automation Projects Fail with Anthony CatacchioEpisode 237-238: High-Throughput Microbial Screening with Sebastian BlumConnect with Tibor Anderlei:LinkedIn: www.linkedin.com/in/tibor-anderlei-66342411/Kühner Shaker website: www.kuhner.comShaking Technology Forum: www.shakingtechnology.comSupport the show

Why do small-scale bioprocess experiments often fail to translate in scale-up despite “perfect” results on paper?Tibor Anderlei, Chief Scientific Officer and leader of customer support at Kühner Shaker, has spent three decades solving an issue that frustrates CMC leaders and biomanufacturing teams worldwide. He pioneered online monitoring in shake flasks, co-founded AC Biotec, and now helps organizations avoid costly trial-and-error with high-throughput screening and orbital shaken bioreactors.Topics discussed:Why orbital shaken bioreactors are fundamental to successful bioprocess development (03:11)The gap between educational practices and real-world bioreactor expertise (04:00)Tibor Anderlei’s journey from the Technical University of Aachen to pioneering online monitoring technology in shake flasks (04:27)Reasons why published shake flask and microtiter plate experiments often fail to be reproduced in other labs (09:47)Key parameters frequently omitted from publications—including shaking diameter—and their impact on experiment reproducibility (13:10)Practical considerations for using microtiter plates and tubes, including automation compatibility and critical shaking speeds (14:13)Common scale-up failures due to oxygen limitation and mismatched aeration rates between small-scale and bioreactor systems (22:22)The effect of bioreactor geometry, such as neck shape, on process ventilation and performance (24:49)Smart insight: If scientists want scalable, reproducible success, the path starts with getting the details right—and keeping a sharp eye on both automation trends and the fundamentals of shaken cultures.Listen to the full episode with Tibor Anderlei to unpack the real “missing links” in bioprocess reproducibility and how to bridge small-scale insight to CMC scale-up.Building a robust scale-up strategy requires looking at the process from multiple angles—regulatory, digital, and operational. Listen to those previous episodes:Episode 03 - 04: How to Master Biotech Scale-up Without Guesswork with Leonardo SibilioEpisode 25-26: 9 Critical Steps for a Seamless Transition to Large-Scale ProductionEpisode 231-232: From IND to BLA: The Biologics CMC Decisions That Determine Regulatory Success with Henri KornmannEpisode 233-234: Why Most Bioprocess Automation Projects Fail with Anthony CatacchioEpisode 237-238: High-Throughput Microbial Screening with Sebastian BlumConnect with Tibor Anderlei:LinkedIn: www.linkedin.com/in/tibor-anderlei-66342411/Kühner Shaker website: www.kuhner.comShaking Technology Forum: www.shakingtechnology.comSupport the show

When a single mismanaged tech transfer threatens an entire development program, pressure on CMC leaders and bioprocess teams is intense. The truth? Tech transfers aren’t a black box. They’re complex, but solvable with the right mindset and playbook.In this episode, David Brühlmann explores the practical side of tech transfer and scale-up within the biotech industry. With more than 15 years of experience, he shares personal stories and industry-tested frameworks that help demystify the complexities of transferring technologies between sites or organizations. Instead of focusing solely on technical details, he emphasizes the crucial human and organizational factors that often decide project success or failure.Key topics discussed:How mapping and managing stakeholders can resolve hidden issues and accelerate projects (01:55)Case studies highlighting the importance of environmental factors — like light exposure — in process performance and troubleshooting (05:50)A mass transfer checklist for bioprocess scale-up, with specific focus on equipment-related parameters (07:09)The build vs. outsource dilemma: how to choose what to keep in-house and what to partner out, depending on company strategy and project phase (08:05)A 12-week tech transfer preparation protocol, covering foundations, risk mitigation, and execution readiness (10:16)Lessons on leadership, prioritization, and effective delegation to avoid personal and organizational bottlenecks (13:28)Whether you're overseeing a complex CMC program, navigating CDMO relationships, or planning your next scale-up, this episode offers concrete steps to cut through confusion and deliver results.If you’re interested in the ideas discussed, here are some of the guests David referenced in this episode.Episodes 91 - 92: Mass Transfer Secrets: Mastering Bubbles and kLa from Bench to Large-Scale Production with Lars Puiman & Rik VolgerEpisodes 79 - 80: Think Before You Build: Holistic Approaches to Biotech Facility Design with Alfredo Martínez MogarraEpisodes 57 - 58: Crafting a Solid CMC Strategy: Key Factors and Common Pitfalls with Matthias MüllnerEpisodes 23 - 24: Strategies for Success: Master CMC Development with Gene LeeSupport the show

What if the hidden cost of your bioprocess lies not in the technology, but in what you don’t document?Too often, biotech teams discover too late that their “proven” process is just an illusion, propped up by undocumented tricks and missing critical parameters. In this episode, David Brühlmann strips down the assumptions behind scale-up and tech transfer, exposing the silent risks that threaten CMC milestones and market launches alike. After 15 years guiding biotech projects from bench to clinic, he’s felt the pain of process gaps, regulatory curveballs, and million-dollar mistakes. Here, he turns that experience into a tactical guide designed to save you from the same pitfalls.In this episode, you’ll learn about:The 6-pillar approach to turning tech transfer into a managed process, rather than a gamble (03:09)Why mass transfer physics and factors like kLA are critical—and how they can make or break a process at scale (05:12)The importance of analytical comparability, including the common blind spots in sampling plans and method validation (07:19)Establishing a solid Quality by Design (QbD) foundation and defining critical quality attributes before transfer, not after failures (08:33)Stakeholder management and why non-technical challenges often derail projects (with more on this in Part 2) (10:09)Evaluating CDMO partners: What selection criteria really matter for long-term success and risk mitigation (11:03)Strategic decision-making: Building core capabilities versus outsourcing, and how to avoid unnecessary costs and delays (12:22)This episode sets the stage for Part 2, where David Brühlmann will share practical stories and detailed frameworks for real-world implementation. If you manage bioprocess scale-up, tech transfer, or CMC development, you’ll find plenty of actionable insights to apply in your own work.If you’re interested in the ideas discussed, here are some of the guests David referenced in this episode.Episodes 91 - 92: Mass Transfer Secrets: Mastering Bubbles and kLa from Bench to Large-Scale Production with Lars Puiman & Rik VolgerEpisodes 79 - 80: Think Before You Build: Holistic Approaches to Biotech Facility Design with Alfredo Martínez MogarraEpisodes 57 - 58: Crafting a Solid CMC Strategy: Key Factors and Common Pitfalls with Matthias MüllnerEpisodes 23 - 24: Strategies for Success: Master CMC Development with Gene LeeSupport the show

What if the solution to cell therapy’s biggest cold-chain challenge comes from the biology of Arctic fish?This conversation features Steve Oh, a leader in advanced bioprocessing, whose career has placed him at the intersection of stem cell biology, process engineering, and clinical translation. Steve Oh joins David Brühlmann to share how XT Thrive®—a next-generation cryopreservation solution drawing from nature’s antifreeze proteins—lets cells survive, thrive, and simplify manufacturing from the bench to the clinic.Episode highlights:Biological insights from Arctic fish and their translation into synthetic peptide chemistry for cell preservation (00:23)The effect of ice crystal formation on cellular damage, and how XT Thrive® minimizes this compared to DMSO (05:32)Simplified logistics: reduced risk of contamination, elimination of post-thaw wash steps, and implications for therapy delivery to remote locations (07:23)Applicability beyond single cells—preserving organoids and potential implications for tissue engineering (09:50)The ease of transitioning from DMSO to the new solution in established lab protocols (10:49)Broader industry challenges: maintaining purity, process optimization, and reducing cost of goods in cell therapy manufacturing (12:03)Promising innovations in rapid cell type differentiation and barriers to scaling transformative biotech (12:50)The importance of supporting innovative therapies beyond short-term ROI (14:17)Smart insight:Next-generation cryopreservation solutions address more than just viability—they simplify transport, reduce costs, lower hands-on time, and help ensure therapy reaches patients in remote locations in optimal condition. As Steve Oh observes, these advances are critical for reducing the cost of goods, improving consistency, and enabling truly scalable cell therapy manufacturing.If you’re interested in this topic, check out these episodes, where we explore how Minnesota’s frozen forests inspired a new wave of biotech innovation—transforming how life-saving cells are frozen, stored, and shipped.Episodes 161 - 162: How to Achieve 85%+ Cell Recovery Without DMSO's Toxic Side Effects with Jeffrey AllenThis is Steve’s second appearance on the podcast. You can also catch his earlier conversation with David, where they explored the challenges and opportunities of cell and gene therapy.Episodes 11 - 12: From Lab to Patient: Steve Oh’s Guide to Mastering Cell Therapy Process Development.Connect with Steve Oh:Email: [email protected]: www.linkedin.com/in/steve-oh-4946261/Support the show

Arctic fish survive in waters that would freeze most life solid. Not because they tolerate ice, but because their biology prevents crystals from forming in the first place. That same principle, translated into synthetic peptide chemistry, is now showing performance data that DMSO cannot match. Part 2 is where the science becomes practical.Steve Oh spent 22 years at Singapore's A*STAR accumulating 43 patents across stem cell bioprocessing, microcarrier technologies, and serum-free media. He now advises XTherma, where he has been stress-testing their DMSO-free cryopreservation solution across T cells, MSCs, organoids, and beyond. In Part 2, he brings the data.Key topics discussed:How antifreeze protein-inspired peptide chemistry reduces ice crystal size and protects cells during freezing and thawing (00:23)T cell and MSC performance data comparing XT Thrive to DMSO and CryoStor CS10, including a 2.5-fold increase in cell yield on microcarriers post-thaw (02:23-05:00)Why ice crystal formation causes more damage during thawing than freezing, and how XT Thrive addresses this (05:32)Elimination of the post-thaw wash step and what that means for contamination risk and manufacturing simplicity (07:00)Hold time extended to 24 hours and storage performance across 4°C, -80°C, and -196°C (08:01)Applicability beyond single cells: organoids, islets, and potential implications for organ preservation (09:50)How to transition from DMSO to XT Thrive: GMP grade, Drug Master File, same concentration, no protocol overhaul required (10:49)Broader cell therapy challenges: differentiation time, cell population consistency, and cost of goods (12:03)Smart insight:The transition away from DMSO is more accessible than most scientists assume. XT Thrive is GMP-grade, carries a Drug Master File, and is used at the same 5-10% concentration as DMSO, making it a plug-and-play substitution for most cell types. The manufacturing implications go further: no wash step, extended hold times, and storage stability across all standard temperature ranges simplify both production workflows and cold-chain logistics to remote treatment sites.If you’re interested in this topic, check out these episodes, where we explore how Minnesota’s frozen forests inspired a new wave of biotech innovation, transforming how life-saving cells are frozen, stored, and shipped.Episodes 161 - 162: How to Achieve 85%+ Cell Recovery Without DMSO's Toxic Side Effects with Jeffrey AllenThis is Steve’s second appearance on the podcast. You can also catch his earlier conversation with David, where they explored the challenges and opportunities of cell and gene therapy.Episodes 11 - 12: From Lab to Patient: Steve Oh’s Guide to Mastering Cell Therapy Process Development.Connect with Steve Oh:Email: [email protected]: www.linkedin.com/in/steve-oh-4946261/Support the show

Why do CDMOs keep building bigger stainless-steel facilities while their margins erode and Asian competitors undercut them on price? And what happens when big pharma decides to stop outsourcing altogether? The business model that sustained the industry for two decades is under pressure from every direction, and for many CDMOs, standing still is no longer a neutral position.In Part 2, Juergen Mairhofer, CEO of enGenes Biotech, shifts from the science to the stakes. Having spent over a decade building a company on licensing proprietary microbial technology rather than selling fermentation capacity, he brings a distinctive vantage point on where the CDMO industry is headed and what it will take to stay relevant.Here are some of the topics discussed:The need for innovation to stay competitive against lower-cost regions, and why capacity-focused business models are running out of road (03:08)How continuous manufacturing creates a competitive edge for CDMOs operating in high-cost regions (05:49)Practical advice for piloting continuous processing, building partnerships, and taking calculated risks before competitors do (06:36)The parallel universe of batch and continuous manufacturing, and how this duality will shape the industry over the next decade (08:24)What scientists need to know before spinning out a technology company: customer focus, cash discipline, and why the team is everything (09:49)Big pharma's return to in-house manufacturing and vertical supply chain integration, and why this creates opportunity for innovation-focused partners (12:12)Smart insight: Technology excellence is necessary but not sufficient. Juergen's closing word was simply "don't be afraid" and it carried weight precisely because it was not a platitude. The companies that will matter in ten years are those that start the hard work of innovation now, before the window closes.If you’re interested in exploring more breakthroughs in continuous bioprocessing and the future of biotech manufacturing, check out these past episodes from the Smart Biotech Scientist Podcast:Episodes 85 - 86: Bioprocess 4.0: Integrated Continuous Biomanufacturing with Massimo MorbidelliEpisodes 153 - 154: The Future of Bioprocessing: Industry 4.0, Digital Twins, and Continuous Manufacturing Strategies with Tiago MatosEpisode 155: From Process Bottlenecks to Seamless Production: How Continuous Bioprocessing Changes EverythingEpisode 156: The Hidden Economics of Continuous Processing That Most Biotech Companies OverlookEpisodes 181 - 182: Innovating Continuous Bioprocessing with Vibrating Membrane Filtration with Jarno RobinEpisodes 209 - 210: From Batch to Continuous: Building Innovation Culture in Conservative Biotech Environments with Irina RamosConnect with Juergen Mairhofer:LinkedIn: www.linkedin.com/in/juergen-mairhofer-ab27a5benGenes Biotech GmbH website: www.engenes.ccSupport the show

What if continuous microbial manufacturing wasn't a pipe dream, but a reality quietly reshaping the foundations of bioprocessing?Meet Juergen Mairhofer, CEO of enGenes Biotech GmbH and a scientist with a rare dual fluency in molecular biology and bioprocess engineering. He's not just optimizing at the margins. He's devised a proprietary E. coli platform that radically stabilizes genetic stability and splits cell growth from protein production. Instead of stretching out fermentation for a few more days, he's running continuous E. coli processes for up to 40 days; something most believed impossible.Here's why this conversation is worth your notebook and a second listen:Why the commodity CDMO model struggles with innovation and how enGenes Biotech's model aligns business incentives with process improvement (02:37)Juergen Mairhofer's early experiences blending molecular biology and bioprocess engineering, and how a "DIY" mentality led to entrepreneurship (04:42)Strategy behind developing a proprietary E. coli strain that decouples protein production from cell growth (10:01)The benefits of continuous manufacturing: running up to 40-day E. coli processes, and how this compares to mammalian (CHO) systems (13:57)Economic and operational advantages: reducing facility footprint, lowering CAPEX/OPEX, and the necessity for innovation in global competition (19:25)How enGenes Biotech integrates upstream and downstream operations for fully end-to-end continuous production (17:50)Specific technical challenges: managing genetic drift, sterility, equipment, and process modeling in continuous systems (21:10)Smart insight: Technology excellence is the entry ticket, but it won't sell itself. The companies that will lead the next decade of bioprocessing are those willing to align their business model with process innovation, not just capacity utilization.If you’re interested in exploring more breakthroughs in continuous bioprocessing and the future of biotech manufacturing, check out these past episodes from the Smart Biotech Scientist Podcast:Episodes 85 - 86: Bioprocess 4.0: Integrated Continuous Biomanufacturing with Massimo MorbidelliEpisodes 153 - 154: The Future of Bioprocessing: Industry 4.0, Digital Twins, and Continuous Manufacturing Strategies with Tiago MatosEpisode 155: From Process Bottlenecks to Seamless Production: How Continuous Bioprocessing Changes EverythingEpisode 156: The Hidden Economics of Continuous Processing That Most Biotech Companies OverlookEpisodes 181 - 182: Innovating Continuous Bioprocessing with Vibrating Membrane Filtration with Jarno RobinEpisodes 209 - 210: From Batch to Continuous: Building Innovation Culture in Conservative Biotech Environments with Irina RamosConnect with Juergen Mairhofer:LinkedIn: www.linkedin.com/in/juergen-mairhofer-ab27a5benGenes Biotech GmbH website: www.engenes.ccNext step:Need fast CMC guidance? → Get rapid CMC decision support hereOne bad CDMO decision can cost you two years and your Series A. If you're navigating tech transfer, CDMO selection, or IND prep, let's talk before it gets expensive. Two slots open this month.Support the show

For many biotech innovators, high-throughput screening platforms promise faster discoveries and streamlined workflows. Yet beneath the surface, the reality is more demanding, requiring hands-on expertise, careful assay design, and a sharp understanding of microbial physiology to avoid mistakes that become expensive to fix downstream.David Brühlmann continues his conversation with Sebastian Blum, Market Development Manager in Europe at Beckman Coulter Life Sciences, who brings a practical, unvarnished perspective to high-throughput screening. Drawing on conversations with startups, pharma, and CDMOs, Sebastian digs into what separates "push-button" automation myths from hard-won bioprocess mastery. From evaluating technical fit to troubleshooting real-world applications, he advocates for a nuanced approach, one focused on fit-for-purpose tools and critical thinking over technology hype.In this episode, we discuss:Practical advice for startups considering systems like the BioLector XT Microbioreactor, including the need for technical expertise and tailored applications (02:34)Scenarios where the BioLector XT Microbioreactor is the best fit (flexibility, multiple microorganisms, modular upgrades) (04:22)The most common mistakes scientists make with screening technologies, and why specialized personnel are still essential (06:45)How automation, robotics, and AI are shaping the future of early-stage bioprocess development, and why core engineering principles remain vital (08:14)Tips for evaluating screening tool placement in your process and aligning technology with your application needs (11:13)If you're making decisions about high-throughput screening platforms and want to avoid costly missteps before scale-up, this episode delivers the clarity you need.Connect with Sebastian Blum:LinkedIn: www.de.linkedin.com/in/sebastian-blum-76240b3bBeckman Coulter Life Sciences: www.beckman.comNext step:Need fast CMC guidance? → Get rapid CMC decision support hereSupport the show

Why do so many promising biotech ideas stall long before they reach the clinic or marketplace? For many, the answer lies hidden in the earliest phase of bioprocess development: upstream processing. It’s where strain selection, media optimization, and culture conditions set the stage for everything that follows. Yet, the smallest missteps here can snowball into expensive roadblocks downstream. This episode of Smart Biotech Scientist Podcast zeros in on why smart screening strategies and the right bioreactor choices early on are the difference between breakthrough and bottleneck.Joining host David Brühlmann is Sebastian Blum, a microbiologist with more than two decades in the life sciences. As Market Development Manager at Beckman Coulter Life Sciences, Sebastian Blum brings firsthand knowledge from collaborating with startups, pharma giants, and CDMOs, bridging theory with the practical realities of modern process development. From commercializing micro-fermentation systems to guiding clients through high-throughput data, his insights come not just from research but real-world applications.Key Topics & Insights:How startups versus large pharma companies differ in process development strategies, including the role of budget, resources, and risk management. (04:27)The importance of designing screening experiments that mirror end-process conditions, and misconceptions around batch versus fed-batch modes. (07:49)Overview of available small-scale bioreactor systems: shake flasks, benchtop reactors, and high-throughput platforms—pros, cons, and ideal use cases. (09:17)Detailed comparison of BioLector XT Microbioreactor, ambr® 15, and ambr® 250 systems, including working volumes, experiment throughput, measurement technology, and cell types suited for each. (13:24)Practical guidance on making the most of high-throughput screening tools and how training, scripting, and collaboration help new users get value from systems like the BioLector XT Microbioreactor. (17:00)This episode offers grounded advice for scientists and founders navigating early-stage bioprocess development, plus a clear look at the technology landscape for microbial screening and optimization. Perfect for those looking to streamline process development and avoid common pitfalls.Connect with Sebastian Blum:LinkedIn: www.de.linkedin.com/in/sebastian-blum-76240b3bBeckman Coulter Life Sciences: www.beckman.comNext step:Need fast CMC guidance? → Get rapid CMC decision support hereSupport the show

For years, mammalian cells and microbial systems have dominated the biotech landscape, shaping the economics and access to life-saving biologics. Yet, in countries where capital and infrastructure are limited, those gold-standard systems bring hefty price tags and daunting complexity. The answer isn't bigger bioreactors; it's alternative biomanufacturing approaches, such as molecular farming. Imagine medicines grown like crops, ready for harvest in days, not months.Meet Waranyoo Phoolcharoen, Co-Founder and CTO of Baiya Phytopharm and Professor at Chulalongkorn University in Bangkok, a scientist who didn't settle for the status quo. As the driving force behind the company, she led the charge to cut through process bottlenecks: navigating regulatory hurdles, scaling plant-based vaccine manufacturing to 5 million doses per month, and reshaping the approach to antibody production for oncology and infectious diseases. Her work proved that plants aren't an alternative. They're a platform.Topics discussed include:How plant-based molecular farming compares to traditional microbial and mammalian cell systems (02:44)The flexibility and rapid scalability of using plants for biomanufacturing (05:06)Speeding up process development with transient expression versus transgenic plants (05:45)Regulatory perspectives and the approval process for plant-produced biologics (06:52)An overview of the ongoing oncology and infectious disease antibody pipeline (08:08)Strategic challenges: balancing product development, revenue, and market-ready innovations through subsidiary companies (09:51)Lessons learned from building a GMP facility capable of 5 million doses per month during the pandemic, with supply chain as the biggest bottleneck (12:50)Future innovations in molecular farming and the role of plant platforms in medicine production (14:47)Smart insight:Platform choice matters. If you're struggling with long development timelines or scale-up challenges, it may not always be the molecule. It may be the system you're using. Molecular farming offers a different set of trade-offs: faster development, flexible scaling, and a practical alternative worth considering before defaulting to a single platform.If you’re interested in other unconventional biological platforms reshaping biomanufacturing, don’t miss these episodes exploring emerging production technologies:Episodes 141 - 142: How Microalgae Cuts Antibody Costs by 70% and Redefines Biomanufacturing with Muriel BardorEpisodes 163 - 164: How Moss Enables Production of Unproducible Protein Therapeutics with Andreas SchaafEpisodes 229 - 230: Cyanobacteria Biomanufacturing: Achieving Carbon-Neutral Production at Lower Cost Than Fermentation with Tim CorcoranConnect with Waranyoo Phoolcharoen:Email: [email protected] Phytopharm website: www.baiyaphytopharm.comNext step:Need fast CMC guidance? → Get rapid CMC decision support hereSupport the show

Imagine producing life-saving antibodies or vaccines not in sprawling stainless steel facilities, but in sunlit greenhouses, inside living, breathing plants.Waranyoo Phoolcharoen, Co-Founder and CTO of Baiya Phytopharm and Professor at Chulalongkorn University in Bangkok, leads the charge in molecular farming in Thailand, pioneering a shift from traditional biomanufacturing toward using whole plants as responsive biofactories. With a unique background in both pharmaceutical sciences and plant biotechnology, she has taken her research out of the academic silo and into the world, founding a clinical-stage company determined to make vaccines and therapeutic proteins accessible where they're needed most.In this episode, we cover:Waranyoo Phoolcharoen's personal journey: from an accidental start in plant biotechnology to making a global impact with molecular farming (03:57)The pivotal moment that shifted her focus from publishing papers to translating research into real-world solutions (06:12)The initial steps and uncertainties of co-founding Baiya Phytopharm in Thailand (07:12)How 'the plant of life' philosophy drives their biopharma platform, and why whole plants (not just cell cultures) are used as biofactories (09:56)Key mindset shifts when transitioning from academia to entrepreneurship, including the importance of teamwork and commercial thinking (12:55)Strategies for making impact-driven biotech startups in resource-constrained environments, and why courage and speed matter (15:50)Insights into the biotech and pharmaceutical landscape in Southeast Asia, including opportunities and challenges for innovators (19:27)Smart insight:The most important mindset shift from scientist to entrepreneur isn't technical; it's learning to ask different questions. Not "is this interesting?" but "who will pay for this, and does it make commercial sense?" As Waranyoo puts it, when you have the right question, it leads to the right answer.Stay tuned for Part 2, where we'll explore platform capabilities and Asia's first plant-derived COVID-19 vaccine to enter clinical trials.If you’re interested in other unconventional biological platforms reshaping biomanufacturing, don’t miss these episodes exploring emerging production technologies:Episodes 141 - 142: How Microalgae Cuts Antibody Costs by 70% and Redefines Biomanufacturing with Muriel BardorEpisodes 163 - 164: How Moss Enables Production of Unproducible Protein Therapeutics with Andreas SchaafEpisodes 229 - 230: Cyanobacteria Biomanufacturing: Achieving Carbon-Neutral Production at Lower Cost Than Fermentation with Tim CorcoranConnect with Waranyoo Phoolcharoen:Email: [email protected] Phytopharm website: www.baiyaphytopharm.comNext step:Need fast CMC guidance? → Get rapid CMC decision support hereOne bad CDMO decision can cost you two years and your Series A. If you're navigating tech transfer, CDMO selection, or IND prep, let's talk before it gets expensive. Two slots open this month.Support the show

Picture a new bioprocess automation project: ambitious, expensive, and packed with promise. But after months of development, your team discovers a flaw that could have been caught with a simple mockup and a few sticky notes on a whiteboard. This episode confronts the real cost of skipping discovery, premature automation, and the myth that faster engineering always means faster solutions.Anthony Catacchio, CEO of Product Insight, continues his conversation with David Brühlmann to untangle the realities of automation strategy in biotech. Drawing from years of building robotics for high-stakes labs, Anthony explores why "minimum testable product" consistently outperforms "minimum viable product" when budgets, timelines, and patient outcomes are on the line.Highlights from the episode:When custom robotics development is genuinely justified — and the conditions that determine whether a large-scale automation investment makes sense for your organization (02:59).Tech demos and usability demos: how to test the hardest parts of your system concept in isolation before committing to full development (06:37).Minimum testable product vs. minimum viable product: why rushing to viable in hardware development is a costly mistake, and how controlled pilot deployments generate the learning that actually accelerates your program (07:37).Why testing in the real operating environment — not a simulated lab setting — is the only way to surface the hidden requirements that will determine whether your automation succeeds or fails (08:29).The "go fever" trap: why problems discovered late in development get buried rather than fixed, and how front-loading validation protects both your timeline and your budget (10:16).The single most practical question a biotech scientist can ask to determine whether a process is a genuine automation candidate: how much are you thinking while you do it? (16:02).Where AI and machine learning deliver real value in bioprocess research — and why the more urgent question is not how to automate a process, but how to redesign it to produce better data (17:59).Why capital equipment in biotech labs will need to change fundamentally to collect the volume and quality of data required to make AI-driven insights meaningful (19:01).Smart insight: Automation is not a technology problem, it is a systems development and requirements development problem. The teams that deeply understand their process and environment before touching a line of code or a line of engineering will always outperform those that do not. As Anthony puts it: you need to look at the whole picture.Connect with Anthony Catacchio:LinkedIn: www.linkedin.com/in/anthony-catacchio-b881581bProduct Insight website: www.productinsight.comNext step:Need fast CMC guidance? → Get rapid CMC decision support hereSupport the show

Many bioprocess automation projects fail, not because the technology is wrong, but because no one clearly defined the problem before buying the robot.In this episode, David Brühlmann sits down with Anthony Catacchio, CEO of Product Insight, to explore why rigorous system design and honest problem definition matter more than any individual technology, and how industrial robotics expertise translates directly into smarter lab automation.Highlights from the episode:Why biotech's "special case" mindset around automation is costing companies time and money — and what industrial robotics already has figured out (02:45).How Anthony's cross-industry career — from surgical devices to warehouse robotics — shaped a process-first approach to system design (05:05).The automation paradox: how to increase throughput and reduce errors without eliminating the expert human judgment your process depends on (09:13).Vision-guided robotics, AGVs, and quadrupeds: what has genuinely changed in capability and what that means for bioprocess applications (11:21).Human-bot testing: the low-cost validation method that reveals workflow flaws before a single robot is purchased (15:07).The $1M vs. $10K decision: a real case study where the right answer was walking away from automation entirely (15:54).Why talking a client out of an expensive project is sometimes the highest-value service a technical consultant can deliver (17:38).Building long-term credibility by recommending the simplest solution that actually solves the problem (19:24).Smart insight: The most expensive automation mistake happens at the whiteboard, not on the manufacturing floor. Define the problem with surgical precision before you ever evaluate a solution.In Part 2, the conversation continues with a deeper look at building automation systems that deliver practical solutions to bioprocessing challenges without overengineering.Tune in for practical strategies and honest reflections on automation, system design, and the importance of clear problem definition in biotech hardware development.Connect with Anthony Catacchio:LinkedIn: www.linkedin.com/in/anthony-catacchio-b881581bProduct Insight website: www.productinsight.comNext step:Need fast CMC guidance? → Get rapid CMC decision support hereSupport the show

How solid is your CMC foundation—and what happens if it cracks under pressure?David Brühlmann welcomes Henri Kornmann, former Head of Biologics Innovation Centre at Ferring Pharmaceuticals. From junior CMC scientist at Merck to leading Ferring Pharmaceuticals' first gene therapy approval for bladder cancer, Henri has moved repeatedly between CMC development, GMP manufacturing, and due diligence across some of the industry's most complex programs.His “house building” approach demystifies CMC’s complexity, showing why early diligence paired with regulatory fluency and scientific insight pays dividends for years.Tune in to hear Henri’s practical wisdom distilled through real-world analogies:Building a strong CMC foundation in early phases and why later fixes can be costly or impossible (02:45)Scaling up: supplying Phase 3 with the final commercial process, including robustness and supply chain strategies such as dual sourcing critical raw materials (03:23)Process validation explained: FDA’s three stages, from control strategy justification to continued verification (05:15)Process Performance Qualification (PPQ): what it is, how many batches are needed, and optimizing timing (07:43)Handling lifecycle changes: maintaining process control, adapting to deviations, and improving systems after regulatory approval (09:34)Managing teams, stakeholders, and cross-functional collaboration in CMC programs (11:49)Importance of good project management, access to scientific expertise, and interpreting guidelines for your specific program (12:27)The “half scientist, half lawyer” analogy for mastering both technical and regulatory aspects (15:08)Smart insight:Never underestimate CMC. If you do, you will pay for it later.If this topic resonates with you, here are a few related episodes where we dive deeper into building strong CMC foundations and avoiding costly development mistakes:Episodes 199 - 200: Mastering Quality by Design: From Product Failures to Commercial Success in Biologics CMC DevelopmentEpisodes 189 - 190: Why Smart Biotech Founders Plan CMC First (While Competitors Burn Cash Later)Episodes 23 - 24: Strategies for Success: Master CMC Development with Gene LeeEpisodes 57 - 58: Crafting a Solid CMC Strategy: Key Factors and Common Pitfalls with Matthias MüllnerConnect with Henri Kornmann:LinkedIn: www.linkedin.com/in/henri-kornmann-9b6869Next step:Need fast CMC guidance? → Get rapid CMC decision support hereSupport the show

Seventy percent of FDA Complete Response Letters have a CMC root cause. Most of those failures trace back to decisions made years earlier. Decisions that felt minor at the time and proved impossible to fix later.Henri Kornmann has spent two decades making those decisions the right way. From junior CMC scientist at Merck to leading Ferring Pharmaceuticals' first gene therapy approval for bladder cancer, Henri has crossed between CMC development, GMP manufacturing, and due diligence across some of the industry's most complex programs. His conclusion: a CMC program is like building a house. Get the foundation wrong and no amount of late-stage effort will save you.In Part 1, Henri reveals the decisions that cannot be undone and how to get them right from the start.What you will learn:Evolution of cell bank technology and regulatory expectations (00:33)The impact of weak CMC foundations on late-stage failure (00:51)Lessons learned from Ferring’s gene therapy approval and CMC gap analysis (06:51)FDA statistics on CMC issues in INDs and response letters (08:07)Critical early decisions: cell bank clonality and proper storage practices (10:22)The importance of comprehensive raw material documentation (12:29)Early analytical characterization and discovering molecular “funkiness” before phase trials (13:41)Supply strategy for phase 2—why stability and batch knowledge matter (14:49)Introduction to critical quality attributes (CQA), process parameters, and quality-by-design principles (15:52)Common pitfalls in CQA identification and continued process verification (17:01)Smart insight:The therapies that reach patients aren't built on heroic late-stage rescues. They're built on disciplined early decisions: the right cell bank, the right analytics, the right documentation. Henri's message is unambiguous: there are CMC mistakes you can fix later, and there are CMC mistakes you cannot. Knowing the difference is the foundation of every successful biologics program.In Part 2, Henri walks through scale-up to commercial manufacturing, process validation stages 1 through 3, post-approval control strategy, and the project management and regulatory fluency that separate successful CMC leaders from the rest.If this topic resonates with you, here are a few related episodes where we dive deeper into building strong CMC foundations and avoiding costly development mistakes:Episodes 199 - 200: Mastering Quality by Design: From Product Failures to Commercial Success in Biologics CMC DevelopmentEpisodes 189 - 190: Why Smart Biotech Founders Plan CMC First (While Competitors Burn Cash Later)Episodes 23 - 24: Strategies for Success: Master CMC Development with Gene LeeEpisodes 57 - 58: Crafting a Solid CMC Strategy: Key Factors and Common Pitfalls with Matthias MüllnerConnect with Henri Kornmann:LinkedIn: www.linkedin.com/in/henri-kornmann-9b6869Next step:Need fast CMC guidance? → Get rapid CMC decision support hereSupport the show

What if the future of sustainable manufacturing required no sugar feedstocks, generated minimal waste, and operated carbon-neutral from day one? Ocean-derived cyanobacteria are making this possible—but the path from promising strain to profitable business is littered with synthetic biology casualties. This episode reveals the strategic decisions that separate winners from failures.In Part 2, Tim Corcoran, CEO and Co-Founder of Deep Blue Biotech, exposes the hard truths about commercializing photosynthetic manufacturing: why most synthetic biology companies died when capital dried up in 2023, which infrastructure gaps nearly derail cyanobacteria scale-up, and why building one facility beats building ten. With three decades navigating commercial biotech and operations, Tim shares the disciplined commercialization framework that transforms scientific breakthroughs into economically viable platforms.Topics covered:The strategic advantage of B2B commercialization in consumer care biotech (02:46)Overcoming infrastructure limitations for photobioreactor scale-up and partnering with specialized CMOs (04:50)Building a pilot facility and moving toward technology licensing for global reach (05:33)Location choices for production facilities—comparing natural light, skilled labor, and electricity costs in Portugal and Iceland (08:57)Impact of electricity usage for LED-supported photosynthesis on business viability (10:45)What distinguishes successful laboratory-to-market biotech companies from those that fail, especially in challenging financial environments (11:53)Practical advice for scientists considering entrepreneurship, including partnering with business-minded collaborators and exploring university innovation programs (14:08)Speculation on the broader applications and future of synthetic biology, from biofuels to biodegradable materials and CO₂-absorbing products (15:27)The importance of aligning technical innovation with commercial expertise to create enduring impact (16:38)Strategic insight:Breakthrough science needs disciplined commercialization. Align what your technology naturally excels at with market needs, start where value is highest, and leverage partnerships to scale. As Deep Blue Biotech shows, this is how innovations move from the lab to making a real-world impact.Explore the full story and hear Tim’s advice for both founders and innovators.If you’re interested in other unconventional biological platforms reshaping biomanufacturing, don’t miss:Episode 163-164: How Moss Enables Production of Unproducible Protein Therapeutics with Andreas SchaafEpisodes 141-142: How Microalgae Cuts Antibody Costs by 70% and Redefines Biomanufacturing with Muriel BardorConnect with Tim Corcoran:LinkedIn: www.linkedin.com/in/tim-corcoran-5b10121/Deep Blue Biotech: www.deepbluebiotech.comNext step:Need fast CMC guidance? → Get rapid CMC decision support hereSupport the show